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We have shown that antagomiR inhibition of miRNA miR-21 and miR-196b activity is sufficient to ablate MLL-AF9 leukemia 
stem cells (LSC) in vivo. Here, we used an shRNA screening approach to mimic miRNA activity on experimentally verified 
miR-196b targets to identify functionally important and therapeutically relevant pathways downstream of oncogenic miRNA 
in MLL-r AML. We found Cdkn1b (p27Kip1) is a direct miR-196b target whose repression enhanced an embryonic stem cell–like 
signature associated with decreased leukemia latency and increased numbers of leukemia stem cells in vivo. Conversely, 
elevation of p27Kip1 significantly reduced MLL-r leukemia self-renewal, promoted monocytic differentiation of leukemic 
blasts, and induced cell death. Antagonism of miR-196b activity or pharmacologic inhibition of the Cks1-Skp2–containing 
SCF E3-ubiquitin ligase complex increased p27Kip1 and inhibited human AML growth. This work illustrates that understanding 
oncogenic miRNA target pathways can identify actionable targets in leukemia.
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Introduction
11q23 rearrangements account for ∼10% of chromosomal abnor-
malities in leukemia and result in fusion of the Mixed-Lineage 
Leukemia (MLL) gene with a multitude of partners (such as AF9). 
11q23/MLL rearrangements (MLL-r) are associated with a poor 
prognosis in acute myeloid leukemia (AML). The overall survival 
is only 20–40% with current treatment, perhaps due to the high 
frequency of leukemia stem cells (LSCs; Huret et al., 2001; Cox 
et al., 2004; Somervaille and Cleary, 2006; Döhner et al., 2010; 
Grimwade et al., 2010). Thus, the identification of therapeuti-
cally targetable pathways maintaining LSC self-renewal or sur-
vival is a high priority.
Expression of MLL fusion proteins, such as MLL-AF9, is suffi-
cient to transform normal bone marrow hematopoietic stem/pro-
genitor cells (Corral et al., 1996; Krivtsov et al., 2006; Somervaille 
and Cleary, 2006; Chen et al., 2008b). Thus, new approaches for 
treating MLL-r leukemia use small molecules that specifically 
block the interaction of MLL fusion proteins with transcriptional 
complexes containing Menin (Grembecka et al., 2012), DOT1L 
(Daigle et al., 2011), and BET family proteins (Dawson et al., 
2011) or inhibit key MLL target genes, such as CDK6 (Placke et al., 
2014), which are known to be important for the transformation 
and maintenance of this leukemia subgroup. Although clinical 
trials are still underway for these newer classes of inhibitors in 
a variety of different cancers, reports of resistance mechanisms 
are beginning to emerge (Fong et al., 2015; O’Leary et al., 2016), 
suggesting that novel strategies that synergize with these agents 
to enhance their efficacy or restore drug sensitivity are needed.
MLL-fusion proteins direct expression of the HOXA cluster 
(HOXA9 and HOXA7) and MEIS1 oncogenes, but the role of spe-
cific HOX genes in transformation varies with the MLL-fusion 
partner (Armstrong et al., 2002; Ayton and Cleary, 2003; Kumar 
et al., 2004; So et al., 2004; Erfurth et al., 2008), suggesting 
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that other factors may play a role in the oncogenesis of MLL/
HOX signaling. The evolutionarily conserved miR-196 family 
MIR196B, MIR196A1, and MIR196A2 encoded within the HOX 
gene clusters are overexpressed in AML and share identical seed 
sequences. In particular, MLL-r leukemias overexpress miR-
196b (Jongen-Lavrencic et al., 2008; Li et al., 2008; Marcucci et 
al., 2008; Schotte et al., 2010), and elevated miR-196b expres-
sion in AML is associated with reduced survival (Li et al., 2012), 
suggesting that miR-196b might play an important role in AML. 
In agreement with these observations, we previously showed 
that simultaneous inhibition of miR-21 and miR-196b reduced 
MLL-AF9 LSC and protected mice from established leukemia 
(Velu et al., 2014).
While miRNA target prediction algorithms can provide guid-
ance about potential miRNA-regulated genes, they do not account 
for cellular context or functional relevance, and they penalize 
binding scores for noncanonical miRNA recognition elements. 
Hence, alternate approaches are needed that can identify func-
tionally important direct miRNA–mRNA target interactions 
in specific cellular contexts, such as leukemia. We used a two-
step unbiased experimental workflow combining a biotinylated 
miRNA mimic pulldown approach with pooled in vivo shRNA 
screening to identify miR-196b targets with important functional 
consequences in MLL-r leukemia. We identify Cdkn1b/p27Kip1 as 
a target of miR-196b, whose repression significantly accelerates 
MLL-AF9 leukemia. Follow-up analyses of signaling pathways re-
vealed that when p27Kip1 expression was repressed in MLL-AF9 
AML cells, an embryonic stem cell (ESC)–like self-renewal/pro-
liferation program was activated, while myeloid differentiation 
programming was reduced. Conversely, either specific blockade 
of the miR-196b interaction with Cdkn1b mRNA or small mole-
cule inhibition of SCFSKP2 E3-ubiquitin ligase complex increased 
p27Kip1 protein levels, promoted monocytic differentiation, sig-
nificantly reduced leukemogenic potential, and increased cell 
death of AML cells. Finally, SCFSKP2 inhibition acted synergis-
tically with Menin/MLL (Ml-1), CDK4/6 (Palbociclib), and BET 
(I-BET151) inhibitors to block the growth of human MLL-r–con-
taining AML cells. Thus, our work provides global mechanistic 
insight into the function of an oncogenic miRNA and illustrates 
the utility of exploiting miRNA signaling to identify actionable 
targets in leukemia.
Results
Unbiased global identification of miR-196b functions 
in human 11q23 AM
The miR-196b–directed signaling pathway in cancer, including 
11q23 AML, is largely unknown. To globally define the miR-196b 
direct targets in AML, we adapted a biochemical approach to 
identify the mRNA transcripts bound by miR-196b–contain-
ing-RISC complexes in human AML cells harboring t(9;11), 
MLL-AF9 translocation (THP1 cells; Odero et al., 2000; Nonne 
et al., 2010; Lal et al., 2011). Using a miRNA target pulldown 
approach, transfection of biotinylated miRNA mimics (Bi-miR) 
permits purification of Bi-miR-196b target–containing RISC 
complexes using the biotin tag (Fig. 1 A). Identities of Bi-miR–
associated transcripts were then revealed by microarray analy-
ses, and validated by quantitative RT-PCR (RT-qPCR). We used 
two different human cell lines for pulldown studies: THP1 AML 
cells and HEK293 cells. Human embryonic kidney (HEK) cells 
express HOXA genes and miR-196b, permitting a comparative 
analysis of two miR-196b–relevant cellular contexts, one of 
which is leukemic. In both HEK293 and THP1 cells, Bi-miR-196b 
bound to previously known target HOXA7, which was enriched 
∼500-fold compared with negative control Caenorhabditis ele-
gans Bi-cel-67 pulldown (Fig. 1 C and Fig. S1 A; Yekta et al., 2004; 
Wong et al., 2015). Bi-miR-196b also repressed target protein 
expression (Fig. S1 B). Furthermore, microarray analyses iden-
tified 262 miR-196b target candidates with twofold or greater 
enrichment in Bi-miR-196b pulldown fractions compared with 
Bi-cel-67 control pulldowns in two or more independent exper-
iments using THP1 AML cells (Fig. 1 B and Table S1). Analyses 
of each THP1 AML cell pulldown experiment independently 
identified an additional 1,708 candidate targets enriched at least 
twofold in THP1 cells (Table S1). These targets were reproduc-
ibly enriched greater than twofold in independent Bi-miR-196b 
pulldown experiments in THP1 AML cells, as well as HEK293 
cells (Fig. 1 C and Fig. S1 A). Thus, the biotinylated miRNA pull-
down approach reproducibly captures putative miR-196b tar-
gets from AML cells and also demonstrates context specificity 
for some miRNA target interactions.
To validate that the Bi-miR-196b pulldown assays identify 
novel targets, we first intersected pulldown targets with those 
predicated by computational algorithms PITA (Kertesz et al., 
2007), miRanda (Enright et al., 2003; John et al., 2004; Betel et 
al., 2008), TargetScan7.0 (Lewis et al., 2003, 2005; Agarwal et 
al., 2015), and DIA NA (Maragkakis et al., 2009a,b; Papadopoulos 
et al., 2009). Of the 162 pulldown targets mapped to known gene 
IDs from Fig. 1 B, 90 were not predicted by algorithms, suggest-
ing that an experimental approach can identify novel miRNA 
targets (Fig. S1 C and Table S1). Next, to provide independent 
validation for miRNA binding to genes in our pulldown data-
sets, we manually located miR-196b binding sites with a mini-
mum of six consecutive nucleotide-seed matches beginning at 
either α, β, or γ positions (Ellwanger et al., 2011). These sites 
were queried for binding by Argonaute (AGO) proteins using 
published high-throughput sequencing of RNA isolated by 
cross-linking immunoprecipitation (HITS-CLIP) datasets (Yang 
et al., 2015). CDKN1B is shown as a representative in Fig. S1 D. 
Of the 17 pulldown targets examined, 100% overlapped with at 
least one AGO-CLIP peak and 15/17 showed multiple AGO-CLIP 
datasets overlapping each miR binding site (Fig. S1 E). Using 
luciferase reporter assays, we validated 12/13 target sites lo-
cated in 10 different pulldown target genes for miR-196b bind-
ing and luciferase repression (Fig.  1  D). Finally, we analyzed 
existing RNA-sequencing (RNA-seq) data from E9.5 embryos 
with limiting alleles of miR-196 (196a2+/−;b−/−, 196a2−/−;b+/−, or 
196a2−/−;b−/− versus 196a2+/−;b+/+; Wong et al., 2015). Analysis of 
the RNA-seq data revealed increased expression of Bi-miR-196b 
pulldown targets in a miR-196 allele dose–dependent manner 
(Fig. S1 F and Table S1). In sum, these data demonstrate repro-
ducibility of biotinylated miRNA target pulldowns, and confirm 
the direct binding of miR-196b and/or AGO complexes to pull-
down target mRNAs.
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An in vivo shRNA screen resolves oncogenic miR-196b 
signaling in MLL-AF9 leukemogenesis
To determine targets with functional importance in leukemo-
genesis, we devised an in vivo shRNA screen. Previously, simi-
lar screens have been used to identify novel therapeutic targets 
in MLL-AF9 leukemia or to phenocopy miRNA activity in vitro 
(Mavrakis et al., 2010; Zuber et al., 2011; Miller et al., 2013; Chen 
et al., 2015). Given that miRNA repress target mRNA stability 
and/or translation, we hypothesized that hairpins enriched in the 
shRNA screen would mimic miR-196b oncogenic activity. First, 
we performed an engraftment test on three mice transplanted 
with MLL-AF9 cells transduced with a randomly barcoded lenti-
Figure 1. Unbiased identification of direct miR-196b targets in human 11q23 AML. (A) Schematic of biotinylated miRNA-mimic (Bi-miR) pulldown 
approach. (B) Heat map of putative miR-196b target gene pulldowns enrichments from three independent pulldowns in 11q23 mutant THP1 AML cells. Dis-
played genes were enriched at least twofold in Bi-miR-196b pulldowns relative to matched Bi-cel-67 pulldowns in two of three experiments. The corresponding 
fold change Bi-miR-196b versus Bi-cel-67 inputs are shown for each gene. (C) Independent RT-qPCR validation of miR target mRNA pulldown. The average fold 
pulldown (± SEM) relative to matched input controls for each Bi-cel-67 control (black bars) and Bi-miR-196b mimic (white bars) in at least three independent 
experiments in THP1 cells. Statistical significance by paired t tests for each gene versus Bi-cel-67 control. (D) Functional miR target validation. Average fold 
change ± SEM repression by miR-196b (miR-196b-5p) relative to negative control (NC) of indicated miR-196b binding sites in three independent Luciferase 
reporter assay experiments. Multiple binding sites in the same gene are distinguished by “1” and “2”. Statistical significance was determined using a two-way 
ANO VA versus NC. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. n.s., not significant.
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viral library at constant multiplicity of infection (MOI) ∼0.2 to 
produce one unique barcode per cell after selection with puromy-
cin. DNA from resultant AML in moribund mice was sequenced 
and compared with DNA from nontransplanted, transduced, 
and selected MLL-AF9 cells as input control, quantifying an 
engraftment efficiency of ∼4%. Based on these data, to ensure 
sufficient representation of each experimental hairpin in vivo, 
we estimated that shRNA should be divided into random pools of 
∼100 hairpins per 1 million MLL-AF9 cells transplanted into 10 
mice per pool. Thus, at a 4% engraftment rate, each hairpin was 
represented by 400 cells per mouse.
Given these parameters, to ensure adequate power and feasi-
bility of the in vivo screen we restricted the number of miR-196b 
pulldown targets analyzed. Specifically, we selected 116 screen 
candidates that were enriched in at least one THP1 pulldown 
experiment, 60 of which were also identified in the HEK293 
pulldown and 103 that were predicted targets by computational 
algorithms (PITA [Kertesz et al., 2007], miRanda [Enright et al., 
2003; John et al., 2004; Betel et al., 2008], TargetScan7.0 [Lewis 
et al., 2003, 2005; Agarwal et al., 2015], and DIA NA [Maragkakis 
et al., 2009a,b; Papadopoulos et al., 2009]; Table S1). Priority was 
given to genes with previously validated miR-196b target sites 
such as HoxA7 (Yekta et al., 2004), genes associated with onco-
genic or tumor suppressive pathways such as Cdkn1b (Polyak 
et al., 1994; Zhang et al., 2013), Braf (Rajagopalan et al., 2002), 
Cdk12 (Blazek et al., 2011), Phc2 (Isono et al., 2005), and Mdm4 
(Parant et al., 2001), and genes involved in stemness or differ-
entiation pathways such as Anxa1 (Machado et al., 2016), Epha7 
(Nguyen et al., 2017), Ikzf1 (Winandy et al., 1995; Wang et al., 
1996), and Pou2f1 (Wang et al., 2004). In vivo examination of 116 
candidates involved 632 individual hairpins (4–6 hairpins/gene) 
were divided into 8 pools (Fig. 2 A). Twelve hairpins against four 
control genes were also included in each pool.
As illustrated in Fig. 2 A, pooled shRNA-containing lentivi-
ruses were transduced into MLL-AF9 leukemic splenocytes at 
a constant MOI of ∼0.2, selected with puromycin, and trans-
planted into sublethally irradiated mice (n = 10/pool). Of the 116 
miR-196b target genes screened, 78 genes with at least two hair-
pins per gene showing reproducible effects in at least four mice 
per pool were subsequently scored. 33 genes showed enrichment, 
while 45 were depleted compared with control hairpins (Table 
S1). To test that hairpins were not stochastically selected in vivo, 
we randomly divided mice from each pool into two groups and 
found a significant correlation of hairpin enrichment and/or de-
pletion across replicate mice in the two groups (Fig. 2 B). These 
data indicate a biological function of hairpin activity in vivo, and 
also demonstrate that the shRNA screen was adequately powered 
to resolve miRNA target function in vivo using shRNA.
To illustrate the biological processes impacted by the miR-196b 
target hairpins in our screen, we performed GO-Elite enrichment 
analyses of the 116 genes targeted by hairpins grouped by screen 
input versus screen output categories (enriched and depleted; 
Table S1). To illustrate these data, we created a miR-196b target 
interactome based on these ontologies (Fig. 2 C). Corresponding 
shRNA screen enrichment or depletion scores of genes involved 
in these different functional networks are graphed in Fig. S2 (A 
and B). We note examples in which both enriched and depleted 
hairpins target different genes involved in the same basic bio-
logical processes (e.g., gene expression; Fig. 2 C). To validate our 
pooled screen results, we assayed the activity of two hairpins 
per gene that were enriched in the MLL-AF9 screen against can-
didates from each biological process for in vivo effects of target 
repression on (1) disease latency as measured by overall animal 
survival (Fig. 2, D–G; and Fig. S2 C) and (2) knockdown of mRNA 
expression (Fig. S2 D). Compared with MLL-AF9 control (nontar-
geting [NT] or eT shRNA) transplanted mice, two independent 
enriched shRNA against Cdkn1b, Slc9a6, Phc2, and Taf5l (Fig. 2, 
D–G, respectively) significantly accelerated MLL-AF9 leukemo-
genesis, while shRNA against a depleted gene Zcchc9 had no 
effect on latency (Fig. S2 C). In contrast, independent valida-
tion studies using two independent shRNA that were enriched 
against HoxA7, Sptssa, Map2k6, Mdm4, Anapc5, Tmem184c, and 
Hnrnpm showed either incomplete (one out of two hairpins) or 
no (zero out of two hairpins) effect on disease latency in vivo as 
compared with MLL-AF9 control (data not shown). These data 
indicate that cyclin-dependent kinase Cdkn1b (p27Kip1), sodi-
um-hydroxide exchanger Slc9a6 (Nhe6), Polycomb Group mem-
ber Polyhomeotic homologue Phc2, and PCAF-associated factor 
Taf5l represent a select group of miR-196b targets with tumor 
suppressive activity in AML. In sum, repression of a subset of 
miR-196b targets in vivo is selectively enriched by cooperation 
with MLL-AF9 to promote leukemogenesis.
miR-196b direct-target Cdkn1b controls ESC-like programming 
to maintain MLL-AF9 leukemia
To gain deeper mechanistic insight into the contribution of the 
miR-196b targets in AML, we performed transcriptional profiling 
of Cdkn1b (p27Kip1) and Phc2 knockdown cells. Cdkn1b and Phc2 
were robustly selected in Bi-miR-196b pulldown experiments, 
both are associated with cell cycle/cell death processes, indepen-
dent shRNA targeting Cdkn1b or Phc2 were selected in the shRNA 
screen, and knockdown of both genes independently accelerated 
MLL-AF9 leukemogenesis in vivo. We identified 113 genes signifi-
cantly differentially expressed in Cdkn1b-knockdown MLL-AF9 
AML compared with NT control (Fig. 3 A; n = 2 per group). Gene 
set enrichment analyses (GSEA) were performed by exploring the 
MSigDB database, as well as other published gene sets previously 
enriched in MLL-AF9 leukemia (Table S2; Krivtsov et al., 2006; 
Somervaille et al., 2009). As expected, genes up-regulated in Cd-
kn1b-knockdown MLL-AF9 leukemia positively correlated to cell 
cycle (e.g., Cdk4 and Ccnd2). However, up-regulated genes also 
strongly correlated to an ESC core gene set (e.g., Hadh, Lmnb1, 
Msh2, and Prmt1; Fig. 3 B; Wong et al., 2008). This enrichment is 
not simply associated with accelerated leukemia pathogenesis, 
as Phc2 knockdown similarly accelerated leukemia, but showed 
reduced expression of the same ESC core gene set (Fig. S3, A and 
B; and Table S2). Instead, Phc2 knockdown leukemia showed 
increased expression of an adult stem cell gene set (Fig. S3 B; 
Wong et al., 2008), which was conversely down-regulated in 
Cdkn1b-knockdown MLL-AF9 leukemia (Fig. S3 C). Thus, there 
appear to be multiple miR-196b targets regulating distinct stem 
cell transcriptional programs important for the pathogenesis of 
MLL-AF9 leukemia. Importantly, genes down-regulated upon 
Cdkn1b knockdown in MLL-AF9 AML correspond with a poor 
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Figure 2. An in vivo shRNA screen functionally dissects miR-196b networks in MLL-AF9 leukemogenesis. (A) Schematic overview. In vivo shRNA-positive 
selection screen of miR-196b-pulldown targets in primary MLL-AF9 leukemia. Leukemic splenocytes were transduced with eight different lentiviral shRNA 
pools against 116 miR-196b target genes and transplanted into recipient mice (n = 10 mice/pool). Sequencing of pretransplant pools (input) versus leukemic 
splenocytes (from moribund mice) identified 33 enriched and 45 deleted genes of at least two hairpins/gene over input control. (B) Replicate assay correlation. 
For each enriched and depleted hairpin, recipient mice were divided into two groups/pool (n = 4–5 mice/group/pool) and plotted. The relatedness between 
these two groups of mice was evaluated by Pearson correlation demonstrating that in vivo selection of hairpin activity is not stochastic (r = 0.8567). Examples 
of genes with enriched (Scl9a6, Phc2, Sptssa, Taf5l, and Cdkn1b) or depleted (Zcchc9) shRNA are color coded. (C) Network analysis of screen targets by gene 
ontology biological processes. RNAi screen enriched gene nodes (red), depleted gene nodes (blue), and unchanged gene nodes (white). Protein–protein inter-
actions are denoted by black edges and putative miR-196b target transcript interactions experimentally identified in miR target pulldown assays are denoted 
by gray edges. (D–G) In vivo validation of positive selection of individual targets. Kaplan-Meier survival curves of mice transplanted with MLL-AF9 leukemia 
expressing individual shRNA hairpins against the indicated genes (n = 4 mice/group; 2 hairpins/gene). Non-targeting (NT) or EV (eT) were used as controls. miR-
196b pulldown targets Cdkn1b (D), Slc9a6 (E), Phc2 (F), and Taf5l (G) accelerated leukemia lethality. Significant p-values are reported by Log-rank (Mantel-Cox) 
test for each hairpin compared with control. *, P ≤ 0.05; **, P ≤ 0.01; ****, P < 0.0001.
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prognosis gene signature in AML (Table S2; Yagi et al., 2003). 
Given the high frequency of MLL-r leukemia stem cells, which 
correlates with prognosis (Huret et al., 2001; Cox et al., 2004; 
Somervaille and Cleary, 2006; Döhner et al., 2010; Grimwade et 
al., 2010), and the stem cell signature activated by Cdkn1b knock-
down, we focused subsequent studies on understanding the role 
and therapeutic potential of p27Kip1 in AML.
Based on enrichment for the ESC core gene set (Wong et al., 
2008), we hypothesized that Cdkn1b knockdown would corre-
spond to greater leukemia stem cell (LSC) activity, which may 
explain its accelerated phenotype. To this end, we used fresh 
c-Kit+ MLL-AF9 leukemic splenocytes from moribund animals to 
quantify colony-forming cells (CFCs) in vitro and the frequency 
of LSC by limiting cell dilution transplantation in vivo (Fig. 3 C). 
While MLL-AF9 cells freshly transduced with Cdkn1b or NT con-
trol shRNA exhibit no differences in clonogenicity or replating 
potential (Fig. S3 D), c-Kit+ Cdkn1b-knockdown MLL-AF9 leu-
kemic splenocytes from moribund mice formed significantly 
greater numbers of colonies than shRNA control (Fig. 3 D). Sub-
lethally irradiated mice transplanted with limiting numbers of 
c-Kit+ Cdkn1b or NT control shRNA expressing MLL-AF9 AML 
cells were monitored for survival over 60 d (Fig. S3 E-G), at which 
point LSC frequencies were estimated using the ELDA web tool 
(Hu and Smyth, 2009). Two independent Cdkn1b-knockdown 
tumors had LSC frequencies of 1/152.6 and 1/84.7, which were 
statistically significant from the frequency of LSCs (1/360.9) in 
NT control MLL-AF9 AML (Fig. 3 E). Thus, suppression of Cdkn1b 
increases the number of MLL-AF9 LSCs.
Cdkn1b-knockdown leukemia also showed down-regula-
tion of a mature hematopoietic cell gene set (Fig. 3 F; Ivanova 
et al., 2002). To experimentally validate this observation, we 
performed flow cytometry to examine myeloid differentiation 
markers CD11b and Gr1 on Cdkn1b-knockdown compared with 
NT control MLL-AF9 leukemic splenocytes. As previously de-
scribed, MLL-AF9 AML is characterized by immunophenotyp-
ically mature CD11b+Gr1+ granulocyte/monocyte progenitor 
(GMP)–like cells (Fig.  3  G; Krivtsov et al., 2006; Somervaille 
and Cleary, 2006). In agreement with the gene expression data, 
Cdkn1b-knockdown was associated with significantly reduced 
expression of CD11b on MLL-AF9 leukemic GMPs compared 
with NT control (Fig. 3 H and Fig. S3, H and I). Together, these 
data suggest lowering p27Kip1 levels is important for restricting 
myeloid differentiation and expanding LSCs within the MLL-r 
leukemic state.
In agreement with Cdkn1b-knockdown augmenting LSC ac-
tivity, GSEA analyses showed increased expression of the ESC 
core gene set (Wong et al., 2008), and an independent gene ontol-
ogy analysis revealed significant enrichment in cell proliferation 
and apoptosis processes (Fig. S3 J). It is possible that either sim-
ilar proliferation rates of ESC and of MLL-AF9 LSC (Somervaille 
et al., 2009), or indirect effects on Myc (Kim et al., 2010), may 
explain the enrichment of ESC-like gene sets within cancer-de-
rived gene expression signatures. To this end, we bioinformati-
cally dissected Myc-regulated genes (Kim et al., 2008, 2010) from 
the ESC core gene set (Table S2; Wong et al., 2008). We also used 
a previously published ESC gene set with cell cycle annotations 
removed (Somervaille et al., 2009). Importantly, Cdkn1b-knock-
down cells were significantly enriched for ESC core gene sets that 
were Myc independent or with cell cycle annotations removed 
(Fig. S3, K and L; and Table S2; Somervaille et al., 2009). Together, 
these data suggest that repression of the miR-196b target Cdkn1b 
enhances an ESC-like transcriptional program in leukemia cells, 
and that this gene expression program extends beyond known 
Myc and cell cycle effects. Altogether, these results suggest that 
p27Kip1 regulates (1) expression of an ESC core gene set (Wong et 
al., 2008), (2) LSC activity/clonogenicity, and (3) the differentia-
tion of MLL-AF9 leukemic progenitors.
p27Kip1 interaction with cyclin–CDK complexes 
regulates ESC-like gene expression, MLL-r leukemia 
differentiation, and survival
Given the association of Cdkn1b-knockdown MLL-AF9 leukemia 
gene signature with that of AML with poor outcomes (Table S2; 
Somervaille et al., 2009), we posited that Cdkn1b may have clini-
cal utility in MLL-r AML. As proof of concept, we force expressed 
Cdkn1b and a selectable marker (ZsGreen) in MLL-AF9 leukemic 
splenocytes. An empty vector (EV) served as control. ZsGreen+ 
cells were FACS-sorted and plated in methylcellulose colony as-
says or transplanted into recipient mice (Fig. 4 A, schematic). 
p27Kip1 overexpression significantly inhibited MLL-AF9 colony 
formation in vitro (Fig.  4  A). In vivo, p27Kip1 overexpression 
significantly delayed survival compared with EV control, but 
all mice succumbed to AML (Fig. 4 B). However, leukemic sple-
nocytes harvested from mice transplanted with Cdkn1b-over-
expressing MLL-AF9 cells were completely devoid of ZsGreen+ 
marker expression (black lines) as compared with EV control 
mice (Fig. 4 C, green lines). Moreover, immunoblot analyses re-
vealed similar p27Kip1 protein levels in leukemic splenocytes from 
Cdkn1b or EV control MLL-AF9 transplanted mice (Fig. 4 C). In 
sum, p27Kip1 overexpression is not compatible with MLL-AF9 leu-
kemogenesis in vitro and in vivo.
To understand how p27Kip1 exerts anti-leukemic effects, we 
expressed either WT p27Kip1 (WT p27) or two p27Kip1 mutants 
in primary murine MLL-AF9 leukemia. Mutation of p27Kip1 at 
Ser10 to Ala (S10A) mimics the dephosphorylation of p27Kip1 at 
this residue inhibiting its nuclear export and promoting assem-
bly into cyclin–CDK complexes (Besson et al., 2006). Thus, the 
S10A mutation increases p27Kip1-mediated cell cycle inhibition. 
Conversely, mutation of the amino acids required for p27Kip1 
interaction with cyclins (R30A and L32A) and CDKs (F62A and 
F64A) generates the p27Kip1 (CK−) mutant. The CK− mutant abol-
ishes p27Kip1-mediated cell cycle inhibition (Besson et al., 2006). 
Expression of WT p27 or the S10A mutant induced G1 cell cycle 
arrest (Fig. S4 A) and monocytic differentiation (Fig.  4  D) of 
MLL-AF9 leukemic blasts as compared with EV. The CK− mutant 
expressing cells were similar to EV cells (Fig. 4 D), suggesting 
that cell cycle and differentiation effects are linked. Additionally, 
ESC-like genes Lmnb1, Msh2, and Prmt1 (from Fig. 3 B and Fig. 
S3, F and G) were significantly repressed by WT p27 expression, 
whereas expression of c-Myc and Hadh was unchanged (Fig. 4 E). 
The CK− mutant abrogated repression of Msh2 and Prmt1, while 
repression of Lmnb1 was observed in all groups (Fig. 4 E, com-
pare CK− with EV). This suggests that p27Kip1 interaction with 
cyclin–CDK complexes is important for the expression of a sub-
Meyer et al. 
miR-196b controls leukemia stem cell activity
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20171312
2121
Figure 3. miR-196b targets Cdkn1b to regulate leukemia stemness and differentiation programs in MLL-AF9 leukemia. (A) Heatmap of gene expression 
in Cdkn1b shRNA-knockdown and NT-shRNA control leukemias. Hierarchical clustering of 113 differentially expressed genes showing greater than twofold 
change in expression by RNA-seq analysis of NT-shRNA control (n = 2) or Cdkn1b shRNA (n = 2) expressing MLL-AF9 leukemic splenocytes. (B) GSEA plot 
ranking ESC core gene set along descending fold change gene expression in Cdkn1b-knockdown (n = 2) versus NT control leukemias (n = 2) by RNA-seq. 
Expression of the top subset of leading edge genes is shown. NES, normalized enrichment score. (C) Schematic illustrating in vitro colony forming assay and 
in vivo limiting cell dilution transplantation assay to quantify functional stem cells from freshly isolated Cdkn1b shRNA and NT control MLL-AF9 leukemias. 
(D) In vitro leukemic stem cell analysis. Average CFU ± SEM from c-Kit+ leukemic splenocytes from individual Cdkn1b shRNA (n = 3) or control shRNA MLL-AF9 
moribund mice. Mean numbers of CFU ± SEM indicated below. A representative experiment is shown. Statistical significance evaluated by t test. *, P ≤ 0.05; 
**, P ≤ 0.01. (E) In vivo quantitation of leukemic stem cells by limiting dilution. Sublethally irradiated mice transplanted with a cell dose range of 1,000, 600, 
300, 100, and 30 cells (n = 6 mice/dose) were followed for 90 d. LSC frequencies and statistical comparisons for pairwise differences in active cell frequencies 
(table and log-fraction plot) between Cdkn1b-knockdown groups and NT control group were calculated by ELDA software (see Fig. S3 [E–G] for corresponding 
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set of ESC-like genes regulated in response to p27Kip1 signaling 
in leukemia cells. Moreover, WT p27 and S10A, but not CK− ex-
pression, significantly reduced MLL-AF9 clonogenicity (Fig. 4 F). 
Next, we extended these analyses into three human MLL-r AML 
cell lines with differing levels of miR-196b expression (Fig. S4 B). 
Similar to murine AML, human AML cells expressing WT p27 
and the S10A mutant, but not the CK− mutant, underwent G1 ar-
rest (Fig. S4 C) and were counter-selected over time (Fig. 4 G). Al-
together, these data demonstrate that elevating p27Kip1 has tumor 
suppressive activity in both human and murine MLL-r AML at 
least in part through coordinated induction of growth arrest and 
differentiation, and repression of ESC-like gene expression.
p27Kip1 as a therapeutic target in MLL-r leukemia
Given that Cdkn1b overexpression had anti-leukemic effects 
(Fig. 4), we next tested whether disruption of mechanisms regu-
lating endogenous p27Kip1 protein expression and turnover would 
also negatively affect MLL-AF9 leukemogenicity. First, we dis-
rupted the miR-196b direct interaction with Cdkn1b mRNA using 
sequence-specific miRNA target site blockers (TSB) constructed 
with locked nucleic acid (LNA) chemistry (Petersen and Wengel, 
2003; Fazi et al., 2005; Ceppi et al., 2009; Wynendaele et al., 2010; 
Dajas-Bailador et al., 2012). Primary murine MLL-AF9 leukemia 
cells were treated with TSB sequences homologous to the vali-
dated miR-196b binding site in the Cdkn1b 3′UTR (Fig. 1 D), as 
well as anti-miR-196b-5p and scrambled nontargeting control 
LNAs. Anti–miR-196b (positive control) or any of the miR-196b-
Cdkn1b TSB treatments significantly reduced colony formation 
(Fig.  5  A) accompanied by derepression of p27Kip1 protein ex-
pression compared with NT control LNA (Fig. 5 A, immunoblot). 
These data indicate that the miR-196b/Cdkn1b signaling axis is 
important to maintain MLL-AF9 clonogenic capacity.
In addition to miR-196b regulation, the ubiquitin-protea-
some pathway regulates p27Kip1 protein expression. The F-box 
protein S-phase kinase-associated protein 2 (Skp2) is the sub-
strate recognition subunit of the SCF E3 ubiquitin ligase complex 
(SCFSkp2) that targets proteins including p27Kip1 for proteasome 
degradation (Carrano et al., 1999; Sutterlüty et al., 1999; Tsvetkov 
et al., 1999; Kossatz et al., 2004). Thus, an orthogonal way to ele-
vate p27Kip1 therapeutically would be to block SCFSkp2-mediated 
protein turnover. SLZ P1-41 is a small molecule inhibitor of the 
SCFSkp2 E3 ubiquitin ligase complex that blocks Skp2–Skp1 bind-
ing. Previously, SLZ P1-41 was shown to decrease ubiquitination 
of SCFSkp2 targets (including stabilization of p27Kip1) and delay 
prostate tumor growth in vivo (Chan et al., 2013). Treatment of 
human MLL-r AML cell lines THP1, MOLM13, and MV4;11 with 
SLZ P1-41 resulted in significant AML cell death in a dose-depen-
dent manner (Fig. 5 B). In contrast, the Cdc34 E2 ubiquitin en-
zyme inhibitor CC0651 (Ceccarelli et al., 2011) had no effect (data 
not shown). Despite differing sensitivities of AML cells to SLZ 
P1-41, the lowest dose that elicited a cell-killing effect was asso-
ciated with increased p27Kip1 protein levels in all cases (Fig. S5 A). 
While there are likely multiple Skp2-regulated proteins that may 
affect AML cell death, these results suggest that accumulation 
of p27Kip1, through disruption of miR-196b and/or Skp2 activity, 
represents a potential new therapeutic opportunity for AML.
Inhibitors of Menin/MLL (Ml-1), BET family (IBET-151), and 
CDK4/6 (Palbociclib) are currently being tested for MLL-r AML 
in the clinic. Given encouraging results with SLZ P1-41, we sought 
to identify a more potent SCFSkp2 inhibitor with a lower relative 
IC50 that could be used to compare the effects of chemically per-
turbing p27Kip1 protein levels to the effects of existing small-mol-
ecule therapeutics. To that end, we evaluated N-(5-(pyridin-3-yl)
quinolin-8-yl)-3-(trifluoromethyl)benzenesulfonamide, re-
ferred to as 22d (Singh et al., 2015). 22d is a potent (0.17 µM IC50) 
inhibitor of the Skp2-Cks1 interaction that is required for SCFSkp2 
ubiquitination of p27Kip1 (Ganoth et al., 2001; Spruck et al., 2001). 
First, we performed dose titrations of 22d measuring cell viabil-
ity after 3 d of treatment to determine the relative IC50 doses of 3, 
0.9, and 0.6 µM 22d in THP1, MV4;11, and MOLM13, respectively 
(data not shown). Notably, p27Kip1 protein levels were increased 
in a dose-dependent manner upon 22d treatment in all three 
AML cell lines (Fig. S5 B). Next, we independently titrated inhib-
itors of Menin/MLL (Ml-1), BET family (IBET-151), and CDK4/6 
(Palbociclib) to identify the relative IC50 for each drug on THP1, 
MOLM13, and MV4;11 human AML cells (data not shown). Third, 
AML cells were treated with three to four doses of Ml-1, IBET-
151, or Palbociclib with and without 22d using a dose range that 
spanned the relative IC50 dose determined for each drug in each 
AML cell line. After 3 d, cell viability was measured relative to 
vehicle control treated cells (Fig. 5, C–E; and Table S3). Synergy 
with 22d plus IBET-151 was observed in THP1 and MV4;11, but not 
MOLM13 cells. Conversely, 22d plus Palbociclib showed synergy 
in THP1, but not MV4;11 or MOLM13 cells. Overall, 22d plus the 
Menin/MLL inhibitor Ml-1 showed the most consistent synergis-
tic effects across all cell lines tested (Table S3). Thus, inhibiting 
Skp2-Cks1 interaction may be a complementary target to those 
currently under investigation. Finally, we determined whether 
primary human MLL-r AML are sensitive to 22d. After 3 d in vitro 
treatment with 22d, we observed growth inhibition of MLL-r 
AML patient samples (Fig. 5 F and Table S3), at 22d concentra-
tions similar to those required to inhibit MLL-r AML cell lines.
Discussion
Target predication algorithms can be useful, cost-effective tools 
to identify miRNA target interactions. However, predication al-
gorithms alone are biased for canonical miRNA seed pairing, pre-
survival curves). Statistically significant differences in LSC frequencies of NTsh control (1/360.9) versus Cdkn1bsh1 (1/152.6); *, P = 0.042 and NTsh control 
(1/360.9) versus Cdkn1bsh2 (1/84.7) ***, P = 0.001. (F) GSEA plot ranking mature hematopoietic cells gene set along descending fold change gene expression 
in Cdkn1b-knockdown versus NT control leukemias by RNA-seq (n = 2/group). Expression of the top subset of leading edge genes is shown. (G) Leukemic GMP 
gating strategy: CD11b+Gr1+ lineage negative (Lin−, red), Lin−c-Kit+ (LK, orange), and LK CD34+CD16/32+ granulocyte monocyte progenitor gate (GMP, green). 
(H) Flow cytometric validation of differentiation status. Representative flow plots (left) and average percentage of CD11bhi and CD11blo leukemic GMP-gate 
populations ± SEM (right) from spleens of moribund Cdkn1b shRNA or control NT shRNA MLL-AF9 mice (n = 3/group). *, P < 0.05 for CD11bhi and CD11blo GMP 
in Cdkn1b shRNA versus NT shRNA by two-way ANO VA.
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dict thousands of targets for a given miRNA, and have no cellular 
context. These shortfalls often lead to a high error rate when at-
tempting to validate miRNA binding and functional importance 
in a biological system. With the use of experimental endogenous 
miRNA–mRNA target discovery methods, including biotinylated 
miR-mimic pulldown, HITS-CLIP, PAR-CLIP, and TAP-Tar, it is 
now believed that noncanonical target recognition (i.e., seedless) 
may play a large role in miRNA-mediated regulation, binding can 
occur outside of the 3′UTR, and target regulation is often con-
text specific. We identified miR-196b targets in human MLL-r 
Figure 4. Cdkn1b/p27Kip1 suppresses MLL-r leukemia in a cyclin–CDK-dependent manner. (A) Top, schematic of CFU and transplantation of ZsGreen+ 
sorted Cdkn1b-ZsGreen (Cdkn1b) or EV-ZsGreen (EV) control expressing MLL-AF9 leukemia cells. Bottom, average number of colonies ± SEM (n = 3 replicates/
group). Mean CFU numbers ± SEM indicated below bar graph. **, P ≤ 0.01 by t test. Immunoblot analyses of p27 performed on cells from CFU assays with 
β-actin as loading control. A representative of two independent experiments is shown with similar results. (B) Kaplan-Meier survival curve of mice transplanted 
with ZsGreen+ Cdkn1b overexpressing MLL-AF9 cells (n = 6/group). Significant differences in survival evaluated by Log-rank (Mantel-Cox) test; *, P ≤ 0.05. 
(C) Counter selection of p27 overexpression in vivo. Flow cytometric analyses for ZsGreen+ expression in EV (green lines) and Cdkn1b-overexpressing (black 
lines) MLL-AF9 leukemic splenocytes from moribund mice. Three representative mice/group are shown. Immunoblot analysis of p27 with β-actin as loading 
control (n = 3 mice/group). (D–F) Functional dissection of p27 activity. WT p27Kip1 (WT p27), nuclear localized p27Kip1 (S10A; increased cell cycle inhibition), or 
CDK-binding domain mutant p27Kip1 (CK−; no cell cycle inhibition) were expressed via lentiviral vectors in murine MLL-AF9 leukemic splenocytes. EV vector 
served as control. Cells were FACS sorted for ZsGreen+ 48 h after transduction and prepared for cytospin (D), RNA (E), or plated in CFU assay (F). Represen-
tatives of two independent experiments with similar results is shown. (D) Cytologies of ZsGreen+ EV, WT p27, S10A, and CK− expressing MLL-AF9 cells were 
visualized with Wright Giemsa stain and imaged at 60× magnification. Bars, 10 µm. (E) RNA extracted from ZsGreen+ EV, WT p27, S10A, and CK− MLL-AF9 
cells was examined by RT-qPCR for changes in c-Myc expression as well as representative non–Myc-regulated (Ccnd2, Hadh, Lmnb1, and Msh2) and ESC core 
genes (Prmt1; n = 2 replicates/group; from Fig. S3, K and L). Expression was compared with Sdha as loading control and is graphed as average relative to EV ± 
SEM. Statistical significance was evaluated for each gene by two-way ANO VA Holm-Sidak multiple comparisons test. (F) Equal numbers of ZsGreen+ EV, WT 
p27, S10A, and CK− expressing MLL-AF9 leukemic splenocytes were plated in triplicate in methylcellulose. The average number colonies ± SEM enumerated 
after 7 d in methylcellulose is shown for three technical replicates with mean CFU ± SEM indicated below. A representative of two independent experiments 
is shown. Statistical significance was evaluated by one-way ANO VA Holm-Sidak multiple comparisons test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 
0.0001. n.s., not significant. (G) Human AML cell lines are organized according to their levels of miR-196b expression (lowest to highest, red gradient triangle; 
see also Fig. S4 B). The relative frequency of ZsGreen+ EV, WT p27, S10A, or CK− transduced THP1, MV4;11, and MOLM13 cells measured over time are shown 
as relative to the proportion of ZsGreen+ cells at the initial time point 48 h post-transduction. A representative experiment is shown.
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AML cells using an experimental biotinylated miR-mimic pull-
down approach, which identified candidate miRNA target genes 
that are not predicted by one or even any prediction algorithm. 
Thus, the use of an experimental approach can identify novel, 
disease-relevant miRNA targets.
miRNA are universally down-regulated in cancers compared 
with normal tissues (Lu et al., 2005), perhaps because miRNA 
can function as tumor suppressors, or miRNA biogenesis may 
be tumor suppressive (Kumar et al., 2007; Chang et al., 2008). 
However, mutations in DIC ER1 have been identified in human 
cancers, and Dicer1 haploinsufficiency is more permissive to tu-
morigenesis than either WT or Dicer1 knockout in mice (Kumar 
et al., 2009). Thus, some degree of miRNA signaling might be 
required for oncogenesis. Indeed, miR-196b provides an exam-
ple of a miRNA signaling network important for the stemness 
and survival of MLL-AF9 leukemia. Functional screening of a 
subset of direct miR-196b targets during leukemia expansion in 
vivo revealed shRNA-mediated repression of targets were largely 
counter-selected or unchanged, yet repression of some targets 
(∼25%) exhibited significant pro-leukemic effects. Thus, miR-
196b signaling balances both tumor growth and tumor-suppres-
sive effects that can be functionally dissected in vivo to identify 
which are important for oncogenic miRNA signaling.
We find Cdkn1b (p27Kip1) is one of the top miR-196b tar-
gets consistently bound by miR-196b in several different tar-
get-validation methods. While miRNA buffer normal stem 
cell maintenance and myeloid differentiation (Emmrich et al., 
2014; Lechman et al., 2016), our studies extend the functional 
requirement for miRNA buffering to malignant stem cell biol-
ogy. Cdkn1b-knockdown by shRNA, which mimics miR-196b 
activity, cooperates with MLL-AF9 to accelerate leukemogen-
esis, increases LSC output, and signals a poor prognosis gene 
Figure 5. RNAi disruption of miR-196b activity or pharmacologic inhibition of SCFSKP2 elevate p27Kip1 and inhibit human AML growth. (A) MLL-AF9 
leukemic splenocytes were treated with indicated LNA and plated in triplicate for CFU assays. The sequences of the LNAs coded for a scramble nontargeting 
control (NT), homologous sequence to miR-196b-5p (anti-196b), or three variant target site–blocking (TSB1-3) LNAs designed with sequence homology to the 
Cdkn1b 3′UTR miR-196b target binding site (miR196b: Cdkn1b). CFU results are shown as the average number of colonies ± SEM for each LNA in two independent 
experiments (left), with mean CFU ± SEM indicated below. Statistical significance was evaluated by t test for anti-196b and TSB LNAs compared with NT control. 
Immunoblots for p27 (right) were performed on LNA-treated CFU to detect target engagement with β-actin as loading control. (B) Average ± SEM percentage 
of alive (AnnexinV−PI−) THP1, MV4;11, and MOLM13 human AML cells treated for 3 d in duplicate with the indicated amounts (μM) of SLZ P1-41 (squares) or 
equivalent volume of DMSO control (circles). Statistical significance was evaluated for each cell line by multiple unpaired t tests Holm-Sidak multiple testing 
correction. *, P ≤ 0.05; **, P < 0.01. Relative miR-196b expression indicated by triangular color scale (see also Fig. S4 B). (C–E) Cell viability heat maps of THP1 
(C), MV4;11 (D), and MOLM13 (E) cells treated for 3 d with single drugs or combinations of 22d, IBET-151, Ml-1, or Palbociclib. Color scale is denoted in C. A 
representative of at least two experiments with similar results is shown for each. See Table S3 for analyses of drug synergies. (F) Primary human MLL-r AML 
patient samples (n = 6) were treated with increasing concentrations of 22d. Cell viability was measured by MTS for all doses after 3-d 22d treatment.
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signature. Conversely, specific disruption of the miR-196b-Cd-
kn1b target interaction increases p27Kip1 levels, significantly 
reducing MLL-AF9 clonogenicity. We note that the effect of Cd-
kn1b-knockdown on MLL-AF9 leukemia maintenance is dissimi-
lar to germline deletion of Cdkn1b (Zhang et al., 2013). Germline 
deletion of Cdkn1b impacts proliferation of normal hematopoi-
etic progenitors (Cheng et al., 2000), a population capable of 
transformation by MLL-AF9 (Krivtsov et al., 2006). Thus, our 
data provide an important distinction between the effects of (1) 
complete deletion of Cdkn1b on MLL-AF9 leukemia initiation 
(Zhang et al., 2013), (2) sustaining low-level p27Kip1 expression 
in leukemia stem cell maintenance, and (3) derepressing p27Kip1 
levels triggering anti-leukemic effects. Altogether, our studies 
support the conclusion that miR-196b activity functions to reg-
ulate the levels of its targets, such as tumor suppressor p27Kip1, 
for leukemia stem cell maintenance and survival.
Repression of Cdkn1b (p27Kip1) was anticipated to influence 
cell cycle and apoptosis since these p27Kip1 functions are well de-
scribed (Polyak et al., 1994; Toyoshima and Hunter, 1994; Katayose 
et al., 1997; Wang et al., 1997); however, our studies also uncov-
ered increased expression of genes associated with an ESC-like 
transcriptional program. Notably, Cdkn1b-knockdown leukemia 
gene expression was enriched for the ESC gene set with cell cycle 
annotations removed (Somervaille et al., 2009). This ESC core 
signature is distinct from an adult stem cell signature (Wong et 
al., 2008) and is enriched in a variety of cancers with high fre-
quencies of cancer stem cells, including functionally validated 
MLL-AF9 LSCs (Somervaille et al., 2009). Whether or not an 
ESC-like program is responsible for cancer stem cell self-renewal 
remains controversial. Oncogenic c-Myc activity might specify 
ESC-like signatures in cancer (Kim et al., 2010); however, we find 
that Cdkn1b-knockdown leukemia was still enriched for a c-Myc–
independent ESC-core gene set. Thus, at least part of p27Kip1 ESC 
programming is c-Myc independent, in agreement with our find-
ing that forced expression of p27Kip1 did not affect c-Myc tran-
script levels. Instead, forced expression of p27Kip1 significantly 
repressed the expression of a subset of these ESC-like genes. In 
sum, these data support an MLL-AF9-miR-196-Cdkn1b pathway 
that controls leukemia stem cell activity through the regulation 
of ESC-like core genes (independent of c-Myc or cell cycle).
Failure to eradicate leukemia stem cells within minimal re-
sidual disease leads to relapse. Consequently, AML subtypes with 
high frequencies of LSC are associated with poorer outcome (van 
Rhenen et al., 2005; Ghiaur et al., 2012; Terwijn et al., 2014). Thus, 
pathways that maintain LSC self-renewal, survival, or suppress 
differentiation represent important therapeutic opportunities 
for the treatment of AML. Our work illustrates how unbiased 
global dissection of oncogenic miRNA signaling can be exploited 
to identify actionable LSC-relevant targets. MLL-AF9 and its 
downstream target HoxA9 transactivate miR-196b expression 
(Popovic et al., 2009; Velu et al., 2014). Here we define a unique 
subset of miR-196b direct targets involved in transcriptional 
and cell cycle processes that help to explain oncogenic miR-196b 
activity. Our work uncovered p27Kip1 as a potential therapeutic 
target for the MLL-r AML subtype. We find that inhibiting the 
E3 ubiquitin ligase activity of SCFSkp2 complexes results in ele-
vation of p27Kip1 protein levels (Chen et al., 2008a; Ceccarelli et 
al., 2011; Chan et al., 2013), and that MLL-r AML are sensitive 
to Skp2 inhibitors. There should be a significant therapeutic 
window for this approach, as genetic deletion of Skp2 in mice 
decreases HSC quiescence and increases HSC proliferation with-
out adversely affecting HSC long-term repopulating potential 
(Wang et al., 2011). Finally, we identify that Skp2 inhibition acts 
synergistically with Menin/MLL, BET, or CDK4/6-targeted ther-
apeutics in AML contexts where treatment as single agents are 
less effective. For example, we observe THP1 cells are relatively 
resistant to Palbociclib as compared with MV4;11 or MOLM13 
cells. However, cotreatment with Palbociclib and the Skp2-Cks1 
inhibitor 22d synergize to induce growth arrest and/or cell death 
of THP1 AML cells, but not MV4;11 or MOLM13 cells. In conclu-
sion, we have elucidated a critical miRNA pathway that can be 
exploited therapeutically to tip the balance from tumor growth 
to tumor suppression. Our study establishes an experimental 
approach for future studies that combines in vitro miRNA target 
identification and in vivo shRNA screening to identify clinically 
important miRNA targets to better understand miRNA signaling 
pathways in cancer.
Materials and methods
Transgenic animals, mouse maintenance, and murine studies
All animal studies were approved by and performed in compli-
ance with the Institutional Review Board Committee on Animal 
Research at Cincinnati Children’s Hospital Medical Center (CCH 
MC). All animal procedures were conducted in accord with the 
Institutional Animal Care and Use Committee at CCH MC. Mouse 
strains used in viral transduction and transplantation studies 
included CD45.2+ C57BL/6-Ly5.2 (JAX and Charles River) and 
CD45.1+ C57BL/6-Ly5.1 (Charles River and CCH MC Compre-
hensive Mouse Core). All transplant recipient mice were male 
between 1–3 mo of age. Murine CD45.1+ MLL-AF9 leukemia was 
a gift from N. Zeleznik-Le (Loyola University Chicago, Chicago, 
IL). MLL-AF9 leukemic splenocytes were expanded in house by 
transplantation into eight recipient mice. Single cell suspensions 
from all moribund mouse spleens were pooled, red blood cells 
(RBCs) lysed by ammonium-chloride-potassium (ACK) buffer 
(Gibco) and archived as ∼15 × 106 cell aliquots in 10% DMSO liq-
uid nitrogen frozen to create a homogeneous stock from which 
all shRNA and gene overexpression studies were performed. For 
shRNA and gene overexpression studies, the replicate hairpins 
per gene and matched controls were performed simultaneously, 
and no blinding was used when recording animal survivals. 
For independent shRNA hairpin validations and gene overex-
pression studies, no statistical method was used to predeter-
mine sample size.
Human AML cell line validation
For cell line validation, DNA was harvested from our THP1, 
MV4;11, and MOLM13 cells actively growing in culture using the 
Blood and Tissue kit (Qiagen). DNA was sent to Genetica DNA 
Laboratories, who performed the SNP analyses. ATCC database 
search for the SNPs reported in our human AML cell lines match 
with 100% identity to the SNPs in the correctly corresponding 
human AML cells at ATCC (Table S3).
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Biotinylated miR mimic pulldown
The biotinylated miRNA mimic–mRNA target pulldown ap-
proach was adapted from Lal et al. (Lal et al., 2011) with modifi-
cations. miRID IAN miRNA mimics hsa-miR-196b and C. elegans 
cel-67 miRNA control were purchased from Dharmacon (Ther-
moFisher Scientific) with a biotin modification at the 3′ end of 
the mature/anti-sense strand (Bi-miR-196b and Bi-cel-67). THP1 
cells were a gift from J. Parentesis (CCH MC), and were SNP veri-
fied by Genetica DNA Laboratories (see Supplemental material). 
HEK293T cells were cultured in DMEM (ThermoFisher Scien-
tific) containing 10% heat-inactivated FBS (Atlanta Biologics), 
Pen-Strep (ThermoFisher Scientific), and l-Glutamine (Ther-
moFisher Scientific). For Bi-miR pulldowns, 0.2 × 106 HEK 293 
cells were plated overnight then cotransfected the following day 
with 100 nM biotinylated miRNA mimics and 0.5 µg/ml GFP-
Max (Lonza) with CaCl2 BBS. THP1 cells were cultured in RPMI 
1640 (ThermoFisher Scientific) containing 20% heat-inactivated 
FBS (Atlanta Biologics), Pen-Strep (ThermoFisher Scientific), 
and l-Glutamine (ThermoFisher Scientific). Cells were main-
tained in liquid culture at subconfluency at low passage at 37°C 
in 5% CO2. For Bi-miR pulldowns, 106 THP1 cells were cotrans-
fected with 100 nM biotinylated miR mimics and 0.5 µg/ml GFP-
Max by electroporation using Amaxa Nucleofector 4D and cell 
line SG kit (Lonza) according to manufacturer instructions.
24 h after transfection, cells were lysed on ice in a cytosolic 
lysis buffer RLN (Qiagen) with 1× HALT protease inhibitor tab 
(Roche), RNaseI (Ambion), and 1 mM DTT (Sigma). Nuclei were 
pelleted at 10,000 g for 10 min at 4°C and discarded. 10% of cy-
tosolic lysates were mixed with TriZol LS (Ambion) as “Input” 
control then frozen at −80°C, while the remaining lysates were 
subjected to “Pulldown” by mixing with M-280 Dynabeads (Invi-
trogen) for 4 h rotating at 4°C. Dynabeads were prepared in ad-
vance for RNA use according to manufacturer instructions, then 
rinsed in cold lysis buffer and blocked with rotation at 4°C for 
2 h with yeast tRNA (Invitrogen) and BSA (Invitrogen). After the 
pulldown incubation, beads were washed on a magnetic stand 
three times with ice-cold wash buffer (Nonne et al., 2010) for 3 
min rotating at 4°C. After the last wash beads were resuspended 
in 0.75 ml TriZol LS and brought to 1 ml with nuclease free water 
(ThermoFisher Scientific) then frozen at −80°C. Isolated RNAs 
of both input and pulldown fractions were examined for target 
enrichment by TaqMan RT-qRCR using the delta Ct method as 
follows in Eq. 1 and Eq. 2 to calculate pulldown enrichment ratios. 
Enrichment = 2-ΔΔCt; Eq. 1 = ΔCt; Eq. 2 = ΔΔCt.
 Pulldown  [   Ct Target Gene   –   Ct SDHA ]  and 
  Input  [   Ct Target Gene   –   Ct SDHA ] (1)
   [   ΔCt Target Pulldown   –   ΔCt Target Input ] (2)
RNA extraction, TaqMan quantitative PCR gene, and miRNA 
expression analyses
RNA was extracted using TriZol or TriZol LS (Ambion) as pre-
viously described (Meyer et al., 2009). Total RNA was con-
verted into cDNA using the High Capacity cDNA Archive kit 
(Life Technologies) for standard gene expression analyses and 
or with miRNA TaqMan RT assays for hsa-miR-196b-5p, mmu-
miR-196b-5p, hsa-miR-196a-5p, and mmu-miR-196a-5p (Life 
Technologies) according to manufacturer instructions. All 
gene and miRNA expression were quantified using TaqMan 
assays (Life Technologies) with the 2× Universal TaqMan Mas-
ter Mix (Life Technologies) according to the manufacturer 
instructions on the StepOne Plus Instrument (Applied Biosys-
tems, Inc.) using equal amounts of starting cDNA. Standard 
inventoried gene expression TaqMan assays recommended by 
the manufacturer (Life Technologies) for best coverage were 
purchased when available. For human gene expression assays: 
CDKN1B (NM_004064.3), SPT SSA (NM_138288.3), HOXA7 
(NM_006896.3), SLC9A6 (NM_001042537.1, NM_001177651.1, 
NM_006359.2), MDM4 (NM_001204171.1, NM_001204172.1, 
NM_001278516.1, NM_001278517.1, NM_001278518.1, NM_ 
001278519.1, NM_002393.4), TAF5L (NM_001025247.1, NM_ 
014409.3), ZCC HC9 (NM_001131035.1, NM_001131036.1, 
NM_032280.2), PHC2 (NM_004427.3, NM_198040.2), PHC3 
(NM_024947.3), TMEM184C (NM_018241.2), HOXA9 
(NM_001277238.1, NM_010456.3), SDHA (NM_004168.2). For 
mouse gene expression assays: HoxA7 (NM_010455.2), HoxB9 
(NM_008270.2), and Meis1 (NM_001193271.1, NM_010789.3), 
Phc2 (NM_001195083.1, NM_001195130.1, NM_018774.4), Taf5l 
(NM_133966.2), Zcchc9 (NM_145453.2), Cdkn1b (NM_009875.4), 
Sptssa (NM_134054.2), Slc9a6 (NM_172780.3), Mdm4 
(Mm.426531), c-Myc (NM_001177352.1, NM_001177353.1, 
NM_001177354.1, NM_010849.4), Ccnd2 (NM_009829.3), Hadh 
(NM_008212.4), Lmnb1 (NM_010721.2), Msh2 (NM_008628.2), 
Prmt1 (NM_001252476.1, NM_001252477.1, NM_019830.3, 
NR_045521.1), and Sdha (NM_023281.1). For human mature 
miRNA expression assays (Life Technologies): hsa-miR-196b-5p, 
hsa-miR-196a-5p, and RNU6B (NR_002752). For mouse ma-
ture miRNA expression assays (Life Technologies): mmu-miR-
196b-5p, mmu-miR-196a-5p, and U6 snRNA (NR_004394). 
Gene expression data were analyzed using the comparative Ct 
method (2-ΔΔCt). SDHA and RNU6B served as loading controls. 
For Bi-miR pulldown validation assays the fold change pulldown 
and inputs (Eq. 1) was calculated (see Biotinylated miR mimic 
pulldown method).
Affymetrix microarray and data analyses
Microarrays were performed that the CCH MC Microarray Core 
Facility. In brief, miR mimic pulldown and input control RNA 
samples were analyzed on an Agilent Bioanalyzer with a RNA 
integrity number >8.0 were selected for microarray process-
ing. 550–1,000 pg of matched input and pulldown RNA samples 
from three independent THP1 experiments and one HEK293 
experiment were processed using the Ovation Pico WTA Sys-
tem V.2 (Nugen) and hybridized to Human Gene 1.0 ST arrays 
(Affymetrix). For HEK293 and THP1 pulldowns, gene expression 
was obtained using the RMA algorithm output from the GCOS 
Affymetrix software with a raw value cut-off of 5 in pulldown 
samples. The Bi-miR-196b input and pulldown samples were 
normalized separately to show change relative to the Bi-cel-67 
control samples. Results were visualized in GeneSpring and Al-
tAnalyze version 2.0.9 for any Ensembl version 72 gene align-
ing probe sets transcript clusters (Salomonis et al., 2009, 2010; 
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Emig et al., 2010). miR-196b target genes are reported for in-
dependent pulldowns with a twofold increase in the miR-196b 
pulldown fractions compared with the cel-67 pulldown controls. 
(Fig. 1 B and Table S1). Venny 2.0 (Oliveros, 2015) or Interac-
tiVenn (Heberle et al., 2015) was used to overlap pulldown target 
lists with target site computational prediction algorithms PITA 
(Kertesz et al., 2007), miRanda (Enright et al., 2003; John et al., 
2004; Betel et al., 2008), TargetScan7.0 (Lewis et al., 2003, 2005; 
Agarwal et al., 2015), and DIA NA (Maragkakis et al., 2009a,b; 
Papadopoulos et al., 2009) to aide identification of pulldown 
targets for the shRNA screen (Table S1).
Target site sequences, cloning, and luciferase reporter assays
Following the miRNA target interaction principles demon-
strated by Kertesz et al. and Ellwanger et al. (Kertesz et al., 2007; 
Ellwanger et al., 2011), a 22-nucleotide (nt) target site was identi-
fied beginning with minimal seed pairing (6 consecutive nt) and 
extending the natural length of the targeting miRNA region of 
homology in the mRNA target. An additional 3 nt flanking at the 
5′ end and 15 nt flanking the 3′ end of the full-length (22 nt) target 
site for a total of 40 nt. We used two different approaches to clone 
target sites into the psiCHE CK2 Dual Luciferase reporter vector 
(Promega). All target site inserts were sequence verified at the 
CCH MC sequencing core.
Either miR-196b target sites sequences (listed below) were or-
dered as double stranded DNA (dsDNA) gblocks from IDT (Inte-
grated DNA Technologies) with 24 nucleotide overhangs on both 
5′ (5′-CGA GCA GTA ATT CTA GGC GAT CGC-3′) and 3′ (5′-TCG AGC 
CCG GGA ATT CGG TTA AAC-3′) ends homologous to the 5′ and 3′ 
ends of the psiCHE CK2 vector (Promega) cut with the Xho1 re-
striction enzyme (New England Biolabs). The target site gblocks 
were cloned into the Xho1 site at the 3′ end of Renilla Luciferase 
in psiCHE CK2 dual luciferase reporter vector using Gibson As-
sembly (New England Biolabs).
CDKN1B: 5′-ATT ATG CAA TTA GGT TTT TCC TTA TTT GCT TCA TTG 
TAC TAC CTG TGT ATA TAG TTT TTA CCT TTT ATG TAG CAC ATA AA-3′.
PHC2: 5′-ACT TCT TTG CCT ATA AAT CTT CCT AGC AGC AAT 
TTG TTG AGC TAC CTG AGG AGG AGG CAG GGC AGA AAG GGC 
GAG GGC CTG CC-3′.
SLC9A6-1: 5′-TTG TAA AAT TTG CAC ATG TGA TTG TGA AGA 
AAT TTG TAC TAC CTA AAA GTC CCA GTG CAT GTC TCT GAA 
TGT GTA AGC TA-3′.
SLC9A6-2; 5′-TTA TTC AAG TTG TAA AAG GTT ATA CAA TAA 
TTT AAC AAC TAC CTT TTT TAT TCT GTC GGG TTA CTG ACC 
TCA CTT TAT GT-3′.
WDR75: 5′-AAA AAC TAA ACG AAA CTT TAG AGA ATG AGC 
TGG TAC AAC TAC CCT TAA CAG AAA ACA TAC CCG CAA TTA 
GTG AGC TTC TT-3′.
TAF5L: 5′-TAA CAA GTA CGT GGT CCG TCT CCA AGA AGA 
CAG CTA CAA CTA CCT TAT CCG CTA CCT CCA AAG TGA CAA 
CAA TAC TGC CCT-3′.
SPT SSA: 5′-TTG TAT TGT TTT TTT TAA GGT TTT TAT TCC 
TTA AAT GTA AAA TGA CTA CCT AAT TTT TTG ATG TAA ATA 
CAT TAA ATT CAA-3′.
ZCC HC9: 5′-TGT TAA TTT TTG ATA ACA GCT AGC ACT ATC 
ATG AGT TAC TAC CTC ATT GTT ACT TTC TAA ACC AGG CCC 
GCT TCA CGA GT-3′.
Elsewise, miR-196b target sites sequences (listed below) were 
synthesized as single stranded complimentary DNA strands 
(Upper and Lower) with 5′ XhoI and 3′ NotI restriction sites on 
the ends (Upper, XhoI/NotI 5′-TCG AG…GC-3′ and Lower, NotI/
XhoI 5′-GGC CGC…C-3′; ThermoFisher Scientific). Equimolar 
amounts of the two strands were annealed before T4 DNA ligase 
(New England Biolabs) mediated ligation to XhoI/NotI cut psi-
CHE CK2 dual luciferase reporter vector (Promega).
HOXA7: 5′-ACT ACC TAC TCC CCT AAA ACT ACC TAT 
TTT GTG CTG GCTG-3′.
MDM4-1: 5′-GAC GAT ATC CCC ACA CTG CCT ACC TCA 
GAG CAT AAA TGCA-3′.
MDM4-2: 5′-CAT GTT TTG ATC CTG ATG CTA CCT TTG 
CTA AAA ATG GCCA-3′.
PHC3-1: 5′-TGA AAG GGC CTC ATC TCA CTA CCT CTC 
TAA GGC CTC TAGC-3′.
PHC3-2: 5′-AGG TTC TTC CTA CTT TTG CTA CCT AAG 
TTT GCA TTT TCTG-3′.
CDKN1B: 5′-CTT ATT TGC TTC ATT GTA CTA CCT GTG 
TAT ATA GTT TTTA-3′.
The number of cells, transfection reagents, reporters, miR 
mimics, and luciferase assay reagents were all titrated and op-
timized for use in 96-well format with the PerkinElmer EnVi-
sion plate reader with injectors. HEK293T cells were seeded in 
regular growth medium, as described above, at 8 × 104 c/ml in 
96-well plates. The following day cells were cotransfected with 
miR mimics and luciferase reporter plasmids using DharmaFect 
Duo (Dharmacon) according to manufacturer’s instructions with 
the following final concentrations per well: 50 nM miR mimic 
(nontargeting or miR-196b-5p purchased from ThermoFisher 
Scientific), 50 ng of the indicated psiCHE CK2 plasmid, 50 ng 
pBlueScript plasmid (to bring total DNA to optimal recommended 
range), and 0.4 µl DharmaFect Duo in a total volume of 100 µl 
growth medium. Cells were incubated with transfection mixture 
for 24 h, and then luciferase activity was measured using the Dual 
Luciferase Assay System (Promega) according to manufacturer 
instructions with the following modifications. Cells were lysed in 
40 µl 1× Passive Lysis Buffer (Promega) for 15 min to 1 h at room 
temperature, and then 30 µl lysate was transferred to a white 
flat-bottom plate. The EnVision injectors were filled with LAR II 
and Stop+Glo (Promega) and the Dual Luciferase Assay protocol 
dispensed 25 µl LAR II, shake plate 1 s at 300 rpm, incubated 10 s, 
read Firefly luminescence (400–700 nM), dispensed 25 µl Stop+-
Glo, shake plate 1 s at 300 rpm, incubated 10 s, and read Renilla 
luminescence. Each miR mimic/reporter construct combination 
was performed in triplicate per assay, and at least three indepen-
dent assays were performed.
Data analyses were performed according to Promega manu-
facturer instructions. In brief, the Firefly luminescence values 
(RLU) measured in each well was normalized for transfection 
efficiency to the Firefly luminescence in psiCHE CK2 EV con-
trol transfected wells for each plate. Then Renilla luminescence 
(RLU) was corrected for transfection efficiency (Renilla RLU/
normalized Firefly RLU) within each well. The replicates for each 
psiCHE CK2 construct cotransfected with nontargeting (NT) con-
trol mimics were averaged and used to calculate the fold change 
in miR-196b-5p transfected wells for each corresponding psi-
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CHE CK2 target reporter construct. Data shown are an average or 
three independent assays.
Pulldown target site comparison with 
argonaute CLIP databases
To further validate the Bi-miR-196b pulldown target binding 
sites, all human cell line CLIP datasets for AGO1-4 CLIP-seq 
studies were downloaded from CLIPdb (Yang et al., 2015) as 
PARalayzer processed .bed files (Table S1). Each dataset was in-
dividually uploaded as a unique track in USCS genome browser 
(Kent, 2002; Kent et al., 2002; Raney et al., 2014) mapped to 
GRCh37/hg19. Since the binding site of the miRNA of interest 
must be known for AGO-CLIP data interrogation, we manually 
searched for each miR1-96b binding site from a filtered selection 
of pulldown targets. All miR-196a-5p and miR-196b-5p miRNA–
mRNA interactions were downloaded from starBase v2.0 (Yang 
et al., 2011) using human assembly hg19, with medium strin-
gency of two or more supporting experiments. This resulted 
in 874 miR-196 target genes. starBase predictions were over-
lapped with THP1 pulldown, HEK293 pulldown, and finally the 
116 shRNA screen candidates using Venny 2.0 (Oliveros, 2015). 
Based on the mature miR-196-5p seed nucleotide sequence target 
sites were manually searched and identified using BLAT feature 
in the Genome Browser, the corresponding genomic coordinates 
are indicated in Fig. S1 (C and D). All target-binding sites were 
counted within 22 nucleotides in either direction of the exact 
target site coordinates.
MOI determination
To determine the amount of lentivirus required to transduce 
murine MLL-AF9 leukemic splenocytes with an MOI of ∼0.2, an 
indirect surrogate measurement of transduction efficiency was 
experimentally determined. Titration of a random barcoded 
lentivirus pool of similar 107 transducing units/ml titer not 
containing any hairpins was used. MLL-AF9 leukemic spleno-
cytes were thawed from liquid nitrogen and allowed to recover 
for 48 h in standard growth medium RPMI 1640 (Gibco) sup-
plemented with 20% FBS (Hyclone), 60 ng/ml stem cell factor 
(SCF), 20 ng/ml IL6, and 20 ng/ml IL3 (Miltenyi Biotech). 106 
MLL-AF9 leukemia cells in 100 µl RPMI 1640 supplemented with 
20% FBS were mixed with 0, 25, 50, 100, 200, 300, or 400 µl len-
tiviral supernatant plus 60 ng/ml SCF, 20 ng/ml IL6, 20 ng/ml 
IL3, and 10 µg/ml polybrene. Cells were incubated with virus for 
6 h at 37°C with 5% CO2. After 6 h, the virus was removed from 
cells and replaced with standard growth medium. Cells were 
allowed to rest of 48 h in standard growth medium, at which 
point they were divided into two replicate wells, one receiving 1 
µg/ml puromycin and the other treated with vehicle. After 48 h, 
cells were mixed with trypan blue and the number of live cells 
in each well was enumerated. Transduction efficiency was cal-
culated using the equation: (no. infected + puro / no. infected 
− puro) – (no. uninfected + puro / no. uninfected − puro) = 
transduction efficiency. Based on prior studies at the Broad In-
stitute, a transduction efficiency between 30–50% yields ∼80% 
of cells getting a single shRNA/cell. We selected the amount of 
virus/106 MLL-AF9 cells that achieved 35% transduction effi-
ciency for our shRNA screen.
MLL-AF9 leukemia engraftment assay, pool size, and animal 
number determination
To determine the size of each shRNA pool to obtain sufficient 
representation of each shRNA hairpin from the resultant leu-
kemias in the in vivo RNAi screen, murine MLL-AF9 leukemic 
splenocytes were prestimulated in growth medium contain-
ing RPMI 1640 supplemented with 20% FBS (Hyclone), 60 ng/
ml mouse SCF, 20 ng/ml mouse IL6, and 20 ng/ml mouse IL3 
(Miltenyi Biotech). 15 × 106 MLL-AF9 cells were transduced in 
growth medium plus 10 µg/ml polybrene with a lentiviral pool 
containing over 199,000 unique barcodes (Broad Institute of 
MIT Harvard) at an MOI of ∼0.1–0.2. After transduction, cells 
were washed then incubated in growth medium for 48 h before 
puromycin selection. Transduced cells and 106 untransduced 
control cells were treated with 1 µg/ml puromycin for 48  h. 
Three sublethally irradiated mice (500 Rad) were each trans-
planted with 106 puromycin-selected MLL-AF9 cells. In addition, 
106 puromycin selected transduced cells were frozen at −80°C 
in PBS as pretransplant control. Moribund mice were sacri-
ficed, spleens were harvested, and single-cell suspensions were 
treated with ACK to lyse RBCs. Genomic DNA was prepared from 
purified MLL-AF9 leukemic cells and pretransplant control cells 
using the QIAamp DNA Blood kit (Qiagen). The Broad Institute 
performed DNA sequencing and read alignment. Unique bar-
code aligned reads for each mouse tumor sample were summed 
and compared with the aligned reads for each barcode in the 
pretransplant control. Random barcoded lentiviruses exert no 
selective pressure on MLL-AF9 cells in vivo as they do not spe-
cifically target any murine coding sequences. By comparison of 
the number of barcodes in the pretransplant hold-back control, 
we calculated an engraftment of ∼4% of bulk MLL-AF9 leuke-
mic splenocytes and thus we estimated that shRNA should be 
divided into random pools of ∼100 hairpins each, with each pool 
containing all control gene (EV, Luciferase, RFP, GFP, and LacZ) 
targeting hairpins, and 10 mice/pool to give sufficient represen-
tation of each hairpin in vivo.
Selection of gene-targeting hairpins for RNAi screen
Candidate miR-196b pulldown targets were identified from three 
independent experiments performed in THP1 AML cells (Table 
S1). Targets also identified in HEK293 pulldown and/or in the 
cumulative predicted miR-196b target list from four computa-
tional prediction algorithms PITA (Kertesz et al., 2007), miRanda 
(Enright et al., 2003; John et al., 2004; Betel et al., 2008), Tar-
getScan7.0 (Lewis et al., 2003, 2005; Agarwal et al., 2015), and 
DIA NA (Maragkakis et al., 2009a,b; Papadopoulos et al., 2009) 
were determined (Table S1). Targets were also examined by gene 
ontology analyses using the ToppGene Suite (Chen et al., 2007, 
2009a,b). Genes with cancer-related biological pathway and 
biological processes gene ontologies, and previously validated 
miR-196b target binding sites were given priority. The final can-
didate targets included in the screen were enriched in at least one 
THP1 pulldown experiment (n = 116; 38/116 were enriched in ≥2/3 
THP1 pulldown experiments represented in Fig. 1 B) and either 
(1) present in HEK293 pulldown experiments (n = 60), (2) pre-
dicted by computational algorithms (n = 103), or (3) in HEK293 
pulldowns and predicted (n = 48; Table S1).
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RNAi screen transduction
MLL-AF9 leukemic splenocytes were thawed from liquid ni-
trogen and allowed to recover for 48 h in standard growth me-
dium RPMI 1640 (ThermoFisher Scientific) containing 20% FBS 
(HyClone) supplemented with mouse recombinant SCF (60 ng/
ml), IL6 (20 ng/ml), and IL3 (20 ng/ml; Miltenyi Biotech). 106 
MLL-AF9 leukemia cells in 400 µl standard growth medium con-
taining FBS were mixed with 100 µl lentiviral supernatant. Cyto-
kines (60 ng/ml SCF, 20 ng/ml IL6 and IL3) and polybrene (10 µg/
ml, Sigma) were added to the final volume. Cells were incubated 
with virus for 6 h at 37°C with 5% CO2, then virus supernatant 
was replaced with standard growth medium containing FBS and 
cytokines. Cells were incubated for 48 h, then for an additional 
48 h with 1 µg/ml puromycin in fresh growth medium. 106 puro-
mycin-selected cells were transplanted into 10 each sublethally 
irradiated (500 Rads) recipient mice, and 5 × 106 cells were held 
back in 100 µl PBS at −80°C as pretransplant input control. The 
transduction transplantation procedure was repeated for each of 
the eight shRNA lentivirus pools. Mice were monitored for illness 
and were sacrificed in accord with Institutional Animal Cancer 
and Use Committee–approved procedures. Leukemic splenocytes 
were harvested and DNA isolated as described.
RNAi screening and data analyses
Leukemic splenocytes were harvested from moribund mice 
transplanted with MLL-AF9 cells transduced with shRNA pools, 
and single-cell suspensions were treated with ACK to lyse RBCs. 
5 × 106 cells/mouse were frozen in PBS at −80°C and 2 × 106 cells 
were examined by FACS analysis for expression of known cell 
surface markers on MLL-AF9 AML cells CD117, CD11b, and Gr1 
expression. The remaining cells were frozen in liquid nitrogen. 
Genomic DNA was harvested from all mouse tumor and hold-
back pretransplant input control samples using the QIAamp 
DNA Blood kit (Qiagen). DNA sequencing and read counts were 
aligned to the unique barcodes for each individual hairpin shRNA 
were performed at the Broad Institute of MIT and Harvard.
To calculate the final representation score for each hairpin, 
the following data analysis pipeline was used. Read counts (in 
counts per million) for each hairpin were normalized to the sum 
of all counts per sample then log2 transformed. Any mouse leu-
kemic splenocyte sample with a sum <10,000 counts per million 
was excluded from further analyses. Note that no control sam-
ples were excluded. The average log2 normalized value for con-
trol hairpins GFP, RFP, and Luc was calculated for each sample. 
Individual experimental hairpins were then normalized to the 
control average for each sample, and finally the fold change en-
richment or depletion scores of each hairpin in the tumor sam-
ples were expressed as relative to pretransplant input control 
sample. Enriched shRNA was scored with a fold change >0 in at 
least 4/10 mice and depleted with a fold change less than −8 in at 
least 4/10 mice. To account for potential off-target effects, final 
shRNA representation lists included only genes with at least two 
hairpins achieving the same directionality in fold change. Genes 
with hairpins scoring on both enrichment and depletion lists 
were considered “no change” and removed from final represen-
tations. To confirm that our scoring method and selection criteria 
were not randomly selecting for enriched or depleted hairpins 
but that these represent reproducible shRNA activity in vivo, 
replicate mice for each hairpin were divided into two groups per 
pool and plotted against each other. The relatedness between 
these two groups of mice was compared by Pearson correlation 
analysis using Prism 6.0.
RNAi screen gene ontology and network analyses
Gene ontology analyses were performed on the datasets: (1) 116 
genes shRNA screen Input shRNA, (2) 33 genes shRNA screen En-
riched, and (3) 45 genes shRNA screen Depleted. GO-Elite analy-
ses were performed on all three datasets as Input in AltAnalyze 
with a z-score cut-off of 1.96, requirement of at least five changed 
genes per category, and the remaining default parameters. Net-
work analyses were performed using AltAnalyze's NetPerspec-
tive. The Cytoscape Sets plugin was used to layout the network 
according to Gene Ontology terms assigned by GO-Elite (labels 
and colored circles added manually).
Lentivirus production, transduction, and gene overexpression
For gene overexpression lentivirus constructs, the pLVX-EIF1α-
IRES-ZsGreen (Clonetech) vector was digested with EcoRI. The 
coding sequence (CDS) for Cdkn1b (NM_009875.4) was down-
loaded from National Center for Biotechnology Infromation. 
Mouse Cdkn1b coding region does not contain any miR-196b 
target sites, thus was used directly for overexpression. cDNA 
sequences of Cdkn1b were ordered as gblocks from IDT with 5′ 
(5′-GAT CTA TTT CCG GTG AAT TC-3′) and 3′ (5′-AGA ATT CCT CGA 
GAC TAG TTC-3′) ends homologous to the 5′ and 3′ ends of the 
EcoRI site in pLVX. The Kozak sequence 5′-GCC ACC-3′ was also 
added just before the ATG start site. Gibson Assembly (New En-
gland Biolabs) was used to recombine the Cdkn1b gblock with the 
pLVX-ZsGreen vector.
Cdkn1b CDS: 5′-ATG TCA AAC GTG AGA GTG TCT AAC GGG AGC 
CCG AGC CTG GAG CGG ATG GAC GCC AGA CAA GCG GAG CAC CCC 
AAG CCT TCC GCC TGC AGA AAT CTC TTC GGC CCG GTC AAT CAT 
GAA GAA CTA ACC CGG GAC TTG GAG AAG CAC TGC CGG GAT ATG 
GAA GAA GCG AGT CAG CGC AAG TGG AAT TTC GAC TTT CAG AAT 
CAT AAG CCC CTG GAG GGC AGA TAC GAG TGG CAG GAG GTG GAG 
AGG GGC AGC TTG CCC GAG TTC TAC TAC AGG CCC CCG CGC CCC 
CCC AAG AGC GCC TGC AAG GTG CTG GCG CAG GAG AGC CAG GAT 
GTC AGC GGG AGC CGC CAG GCG GTG CCT TTA ATT GGG TCT CAG 
GCA AAC TCT GAG GAC CGG CAT TTG GTG GAC CAA ATG CCT GAC 
TCG TCA GAC AAT CCG GCT GGG TTA GCG GAG CAG TGT CCA GGG 
ATG AGG AAG CGA CCT GCT GCA GAA GAT TCT TCT TCG CAA AAC 
AAA AGG GCC AAC AGA ACA GAA GAA AAT GTT TCA GAC GGT TCC 
CCG AAC GCT GGC ACT GTG GAG CAG ACG CCC AAG AAG CCC GGC 
CTT CGA CGC CAG ACG TAA-3′.
The Cdkn1b/p27 Ser10 to Ala mutant (S10A) and p27 cyclin/
CDK-binding mutant Arg30 to Ala, Leu32 to Ala, Phe62 to Ala and 
Phe64 to Ala (CK−) were described previously (Vlach et al., 1997; 
Besson et al., 2006). The point mutations were introduced into 
the murine Cdkn1b CDS (NM_009875.4). The final sequences 
were codon optimized for murine expression using publically 
available software from Integrated DNA Technologies. Sequences 
were ordered as gblocks from IDT with 5′ (5′-GAT CTA TTT CCG 
GTG AAT TC-3′) and 3′ (5′-AGA ATT CCT CGA GAC TAG TTC-3′) ends 
homologous to the 5′ and 3′ ends of the EcoRI site in pLVX. The 
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Kozak sequence 5′-GCC ACC-3′ was also added just before the ATG 
start site. Gibson Assembly (New England Biolabs) was used to 
recombine the Cdkn1b gblock with the pLVX-ZsGreen vector.
Cdkn1b S10A CDS: 5′-ATG TCA AAC GTC AGG GTA TCT AAT GGA 
GCA CCT AGT TTG GAA CGC ATG GAC GCT CGG CAA GCC GAG CAC 
CCC AAA CCC TCT GCC TGT CGG AAC TTG TTC GGC CCT GTT AAT 
CAC GAG GAG CTC ACC AGG GAC CTG GAG AAG CAC TGC AGA GAC 
ATG GAG GAG GCA AGC CAG CGA AAA TGG AAT TTC GAC TTT CAG 
AAC CAC AAA CCA CTG GAG GGC AGG TAC GAG TGG CAG GAG GTG 
GAG AGG GGG TCT CTG CCA GAA TTT TAT TAC CGG CCC CCT CGC 
CCA CCT AAA AGC GCT TGT AAG GTA CTG GCC CAA GAA AGC CAA 
GAC GTA AGT GGC AGC AGA CAG GCT GTT CCC CTC ATC GGG TCA 
CAA GCC AAC TCT GAG GAC AGG CAC CTT GTC GAC CAG ATG CCC 
GAT TCC AGC GAT AAT CCT GCA GGA CTC GCC GAG CAG TGT CCT 
GGG ATG CGA AAA AGG CCA GCC GCT GAA GAC TCT AGC TCT CAG 
AAC AAG AGA GCC AAC CGC ACT GAA GAG AAC GTG TCT GAC GGC 
AGT CCC AAT GCC GGG ACA GTC GAG CAG ACA CCG AAA AAG CCT 
GGA CTC CGA CGG CAG ACG TAA-3′.
Cdkn1b CK− CDS: 5′-ATG AGT AAT GTT AGG GTG TCT AAC GGG 
TCT CCT TCT CTG GAG AGA ATG GAC GCT CGG CAG GCC GAG CAT 
CCG AAG CCA TCC GCC TGC GCC AAT GCC TTC GGT CCT GTG AAT 
CAC GAG GAG CTC ACA AGA GAT CTG GAG AAA CAT TGC CGG GAC 
ATG GAG GAG GCC TCT CAA AGA AAA TGG AAC GCC GAT GCC CAG 
AAC CAC AAG CCT CTT GAG GGT CGG TAT GAA TGG CAG GAA GTC 
GAG AGG GGA TCT CTC CCC GAG TTC TAT TAT CGG CCT CCT CGC CCA 
CCA AAG TCT GCA TGC AAA GTG CTG GCC CAG GAG TCC CAG GAT 
GTG AGT GGA AGT AGG CAG GCC GTC CCT CTG ATA GGT TCT CAG 
GCT AAC TCA GAA GAC AGG CAC CTT GTT GAT CAA ATG CCT GAC 
TCT AGC GAC AAC CCA GCC GGG CTG GCA GAA CAG TGT CCG GGG 
ATG CGC AAG AGG CCA GCC GCC GAG GAC TAT CAT CTC AGA ACA 
AAC GCG CTA ATA GAA CTG AGG AGA ATG TTA GCG ACG GGT CTC 
CTA ACG CAG GCA CAG TGG AGC AGA CCC CCA AAA AGC CGG GAC 
TGC GAC GCC AGA CCT AA-3′.
For lentivirus production, lentiviral vectors Cdkn1b-ZsGreen 
(WT p27), S10A, CK− or EV control were cotransfected with len-
tiviral packaging plasmid Δ8.9 (Naldini et al., 1996) and envelope 
plasmid VsVg (Burns et al., 1993) using TransIT-LT1 (Mirus Bio) 
into Lenti-X 293T cells (Clonetech). Lenti-X 293T (Clonetech) 
cells were cultured in DMEM containing 10% heat-inactivated 
FBS (Atlanta Biologics), Pen-Strep (Gibco), and l-Glutamine 
(Gibco). Virus-containing supernatant was collected 48 and 
72 h post-transfection, and either used immediately or frozen at 
−80°C in aliquots.
MLL-AF9 leukemic splenocytes were transduced as described 
for the RNAi screen, but with a second transduction repeated 
the following day. Cells were allowed to rest of 48 h in standard 
growth medium then sorted for ZsGreen+ expression using Mo-
FloXDP (BD Biosciences) at the CCH MC flow cytometry core. 
104 sorted cells were divided evenly into methylcellulose M3434 
(Stem Cell Technologies) colony forming assays in triplicate, or 
5 × 104 cells were transplanted into sublethally irradiated recip-
ient mice (n = 6 per group). For p27 mutant experiments, RNA 
and cytospins were also performed using ZsGreen+ sorted cells 
48 h post-transduction, and 103 cells were plated in methylcel-
lulose M3434 (Stem Cell Technologies) colony forming assays in 
triplicate. Human AML cell lines were transduced with EV, WT 
p27, S10A, and CK− lentivirus expressing the ZsGreen fluorescent 
marker. AML cell lines were transduced as described for the RNAi 
screen in one round of transduction and allowed to rest for 48 h. 
Beginning at 48 h post-transduction, and every 24 h thereafter 
for a total of 5 d, an aliquot of each group of AML cells were 
examined for ZsGreen+ expression by flow cytometric analyses 
using an LSR flow cytometer (BD Biosciences). The percentage of 
ZsGreen-expressing cells overtime was measured for each group 
and expressed as the frequency of ZsGreen+ cells relative to the 
initial time point at 48 h.
Flow cytometric analyses and cell sorting
For the GMP myeloid differentiation analyses, 5 × 106 MLL-AF9 
leukemia cells were incubated for 1  h at room temperature 
in 50 µl FACS buffer (1% FBS (HyClone), 0.1% NaAzide, PBS) 
with a biotinylated lineage antibody cocktail 0.5 µl/antibody 
CD3 (clone 145-2C11, BioLegend), CD4 (clone RM4-5, eBiosci-
ences), CD8 (clone 53- 6.7, BD Biosciences), CD19 (clone 6D5, 
BioLegend), CD45R (clone RA3-6B2, BioLegend), CD127 (clone 
B12-1, BD Biosciences), and Ter119 (clone Ter-119, BioLegend) 
plus 0.5  µl of CD16/32-PerCP-eF710 (clone 93, eBiosciences), 
CD11b-BV605 (clone M1/70, BD Biosciences), Gr1-PE-Cy5 
(clone RB6-8C5, eBiosciences), CD117-BV650 (clone RAM34, 
BD Biosciences), Sca1-PE-Cy7 (clone D7, BD Biosciences), and 
1.0 µl CD34-BV421 (clone RAM34, BD Biosciences). Cells were 
washed with FACS buffer then resuspended in 50 µl FACS buf-
fer plus 0.5 µl Streptavidin-APC-Cy7 (BD Biosciences) and in-
cubated at 4°C until just before analyzing, cells were washed 
once with FACS buffer, then analyzed on Fortessa 2 flow cytom-
eter (BD Biosciences). For bone marrow chimerism, 106 ACK 
treated bone marrow cells were stained in 100 µl FACS buffer 
with 1  µl FcγRIII/FcγRII block (clone 2.4G2, BD Biosciences), 
1  µl CD45.1-BV605 (clone A20, BioLegend), and 1  µl CD45.2-
FITC (Clone 104, BioLegend) for 1 h at RT. Cells were washed 
and resuspended in FACS buffer plus PI and analyzed on the 
Fortessa 2 flow cytometer. For all analyses, cells were gated on 
the live populations with doublets excluded. Cells analyzed on 
Fortessa 2 flow cytometer (BD Biosciences). All biotin-lineage 
(Lin) positive cells were excluded leaving Cd11b+Gr1+Lin− cells 
from which the c-Kit+ population was further defined as GMP 
by CD34+ and CD16/32+. Leukemic GMP cells were divided for 
CD11bhi and CD11blo or Gr1hi and Gr1lo expression by setting the 
gates for all samples based on the median CD11b or Gr1 expres-
sion in WT MLL-AF9 control cells. For all analyses cells were 
gated on the live populations with doublets excluded.
For isolation of c-Kit+ MLL-AF9 leukemic splenocytes fresh 
or frozen leukemia cells were incubated with mouse CD117 Mi-
crobeads (130-091-224, Miltenyi) according to the manufactur-
er’s instructions. The c-Kit+ and c-Kit− fractions were sorted on 
the AutoMACs Pro (Miltenyi).
Cell cycle analyses
ZsGreen+ EV, WT p27, S10A, or CK− transduced murine MLL-AF9 
leukemic splenocytes and human AML cell lines THP1, MV4;11, 
and MOLM13 were treated with 1  µl Vybrant DyeCycle violet 
stain (ThermoFisher Scientific) at 106 cells in respective growth 
medium and incubated for at least 30 min at 37°C at 5% CO2 in 
accordance with manufacturer instructions. Cells were ana-
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lyzed for violet dye using the violet laser and acquired at <1,000 
events/second on the LSR flow cytometer (BD Biosciences) in lin-
ear scale. Cell cycle analyses were performed on ZsGreen+ gated 
alive single cells using the Cell Cycle platform in FlowJo v10.0.7 
(FlowJo, LLC). Cell cycle analyses were confirmed for each p27 
construct or EV control in all three cell lines in at least two inde-
pendent experiments.
RNA-seq analyses
Leukemic splenocytes were harvested from mice transplanted 
with MLL-AF9 leukemia transduced with either Cdkn1b shRNA 
(n = 2 mice), Phc2 shRNA (n = 3 mice), or NT control shRNA (n 
= 2 matched experimental control mice in Cdkn1b-knockdown 
study group and n = 3 mice matched experimental controls in 
Phc2-knockdown study group). RBCs were lysed with ACK, and 
5 × 106 leukemia cells were lysed with Trizol. RNA quality and 
quantity were measured by Agilent Bioanalyzer at CCH MC Mi-
croarray Core. Then samples with a RNA integrity number >8.0 
were processed by poly-A selection, stranded True-seq, paired-
end 75 bp 20 million reads by the CCH MC Sequencing Core. The 
fastq files were aligned to mouse genome Mm9 using BowTie 2 
and TopHat 2 (Trapnell et al., 2009; Kim et al., 2013). Gene level 
fragments per kilobase of transcript per million mapped reads 
were obtained using Cufflinks 2 (Trapnell et al., 2010) and fur-
ther processed in AltAnalyze 2.0.8 to identify differentially ex-
pressed genes using default parameters moderated t test with 
Benjamini-Hochberg multiple testing correction, raw p-value 
cut-off of 0.05, and an expression cut-off of twofold.
GSEA analyses
Log2 RNA-seq expression derived from total leukemic splenocytes 
from two independent Cdkn1b shRNA (“Cdkn1bsh”) with two in-
dependent NT shRNA controls (“NTsh”), and three independent 
Phc2 shRNA (“Phc2sh”) with three independent NT shRNA con-
trols (“NTsh”) were imported into GSEA v.2.2.0 (Mootha et al., 
2003; Subramanian et al., 2005). A fold change ranked gene list 
was created comparing the Cdkn1bsh or Phc2sh to NTsh control 
samples using the Diff_of_Classes ranking metric and genes were 
sorted by descending order real mode. GSEA analyses were run 
using 1,000 gene_set permutations of gene sets in the website 
gene matrix database with the weighted enrichment statistic. 
Results are reported for the most highly positively correlated 
and negatively correlated hematopoietic-related gene sets with 
leading edge analyses.
To dissect the Myc-regulated, from non-Myc regulated genes 
within with Wong ESC core gene set (Wong et al., 2008), all of 
the Myc ChIP-Chip identified direct target genes in ESC (Kim 
et al., 2008) and the Myc core module genes (Kim et al., 2010) 
were subtracted from the Wong ESC core gene set. Then GSEA 
analysis was performed as described above for enrichment of the 
“Myc-regulated ES core” (n = 168 genes) and “non-Myc regulated 
ES core” gene sets (n = 124 genes) in Cdkn1bsh MLL-AF9 cells 
compared with NTsh control. See Table S2 for gene sets.
Gene ontology analyses
Gene ontology analyses were preformed using ToppFun in the 
ToppGene Suite (Chen et al., 2007, 2009a,b).
In vitro colony forming assays
Equal numbers of cells were mixed with methylcellulose M3434 
complete with cytokines SCF, IL6, IL3, and EPO (Stem Cell Tech-
nologies) according to manufacturer’s instructions in triplicate. 
104 cells/plate were seeded in all studies using transduced bone 
marrow cells, 103 cells/triplicate were divided evenly/plate for 
studies using purified c-Kit+ leukemic splenocytes, and 103 Zs-
Green+ leukemic splenocytes were seeded per plate in triplicate 
for p27 overexpression studies. On day 7 immortalized/trans-
formed colonies >1,000 cells were enumerated. Colonies were 
dissociated with PBS, single cell suspensions were counted, and 
either equal numbers of cells were replated or used in other in-
dicated downstream applications. Each group was performed in 
triplicate and results were repeated in independent experiments 
at least twice.
Limiting dilution transplantation assay
Leukemic splenocytes were isolated from moribund CD45.1 
C57BL/6J mice (BoyJ, Jackson Labs) transplanted with MLL-AF9 
leukemia cells expressing Cdkn1b-targeting or nontargeting con-
trol shRNA. c-Kit+ cells were enriched using the CD117 microbead 
kit and AutoMACS Pro (Miltenyi) according to the manufactur-
er’s specifications and then diluted to 1000, 600, 300, 100, or 30 
cells/200 µl in PBS. BoyJ transplant recipients (n = 6 mice per cell 
dose) were conditioned with a split dose radiation of 500 cGy and 
200 cGy 3 h apart, then cells were injected via tail vein. Recipi-
ents were sacrificed when moribund or at 90 d after transplant. 
Leukemia stem cell frequency was calculated using ELDA soft-
ware (Hu and Smyth, 2009).
Immunoblot analyses
Cells were lysed in radioimmunoprecipitation (RIPA) buffer 
(50 mM Tris, pH 7.4, 1% TX-100, 0.2% Na deoxycholic acid, and 
0.2% SDS, HALT complete tab [Roche]). Proteins were quantified 
using the Pierce BCA Protein Assay kit (ThermoFisher Scientific) 
and equal amounts of protein were run on 4–12% Bis-Tris gradi-
ent gels (Invitrogen) according to manufacturer’s instructions. 
Proteins were transferred by semi-dry electrophoresis (BioRad) 
onto Immobilon-P PVDF (EMD Millipore). Membranes were 
incubated overnight at 4°C with anti-p27 3688 (Cell Signaling 
Technologies) or HoxA7 ab70027 (Abcam), washed then incu-
bated with anti-mouse or anti-rabbit HRP conjugated secondary 
antibodies (GE Healthcare). Membranes were developed on film 
with WesternSure Premium Chemiluminescent Substrate (LI-
COR). The same Immunoblots were reprobed with β-actin clone 
AC-15 (Sigma) as loading control. Biotinylated miRNA target 
immunoblots and p27Kip1 immunoblots were repeated on lysates 
generated from at least two independent experiments each.
In vitro RNAi therapeutic treatments
Standard commercially available NT LNA 5′-ACG TCT ATA CGC 
CCA-3′ and anti–mmu-miR-196b-5p LNA 5′-CAA CAG GAA ACT 
ACCT-3′ were purchased from Exiqon. Custom design LNAs 
(Exiqon) to specifically block miR-196b binding to the validated 
target sites in human and mouse Cdkn1b include TSB1 5′-ATA 
CAC AGG TAG TAC-3′, TSB2 5′-ACA CAG GTA GTA CAA-3′, and TSB3 
5′-ATA TAC ACA GGT AGT-3′. For MLL-AF9 LNA treatments, non-
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targeting control, anti-miR-196b, and custom miR-196b/Cdkn1b 
target site blocker LNAs were purchased from Exiqon. MLL-AF9 
leukemic splenocytes were plated at 5 × 104 c/ml in 96-well plates 
and treated with 500 nM of LNA. Treated cells were incubated 
overnight. 0.21 × 104 cells from each group were retreated and 
plated in triplicate in methylcellulose M3434 in 24-well format. 
Colonies were enumerated after 7 d, and then single cell suspen-
sions were generated and lysed in RIPA buffer for Western anal-
yses. Experiments were repeated three times.
Skp2 inhibitors, cell death, and drug synergy assays
THP1 cells were cultured in RPMI 1640 (ThermoFisher Scien-
tific) containing 20% heat-inactivated FBS (Atlanta Biologics), 
Pen-Strep (ThermoFisher Scientific), and l-Glutamine (Ther-
moFisher Scientific). Cells were maintained at subconflu-
ency and low passage at 37°C in 5% CO2. MV411 and MOLM13 
cells were cultured similarly except in supplemented with 
10% heat-inactivated FBS. For cell death analyses, cells were 
plated in duplicate at 0.3 × 106 c/ml and treated with 0, 12.5, 
25, or 50  µM SLZ P1-41 (Tocris) or equivalent DMSO vehicle 
control and incubated for 3 d. Cells were then stained for An-
nexinV–Pacific Blue (BioLegend) and propidium iodide (PI; BD 
Biosciences) in AnnexinV Binding Buffer (BioLegend) accord-
ing to manufacturer instructions. Cells were analyzed on LSR 
II or Fortessa 2 flow cytometers (BD Biosciences). Results are 
graphed as average percentage alive cells as defined by An-
nexinV− and PI−. The amount of inhibitor chosen for p27 im-
munoblots corresponded with the lowest dose of inhibitor to 
have a significant effect on cell viability in the 3-d treatment 
time course studies. Cells were treated for 24 h with indicated 
amounts of inhibitor then lysed in RIPA buffer and frozen at 
−80°C followed by immunoblot analyses to detect p27. Experi-
ments were repeated at least twice.
For synergy assays, we synthesized the previously published 
Skp2-Cks1 inhibitor N-(5-(pyridin-3-yl)quinolin-8-yl)-3-(tri-
fluoromethyl)benzenesulfonamide, referred to as compound 
22d (Singh et al., 2015), resuspended in DMSO. 22d was titrated 
on THP1, MOLM13, and MV;411 cell lines with and without 
Ml-1 (Sigma), IBET-151 (GSK1210151A, Sigma), or Palbociclib 
(PD0332991, Selleckchem). Three doses of ML1, I-BET151, or Pal-
bociclib were determined by dose titration studies by CellTiter 
Glo assay, and three concentrations surrounding the relative IC50 
concentrations for each drug in each cell line were used for syn-
ergy studies (data not shown). AML cell lines were plated in trip-
licate at 0.106 cells/ml. Cell lines were treated with inhibitors 22d, 
IBET-151, Ml-1, or Palbociclib, or vehicle and cultured for 72 h. 
CellTiter Glo (Promega) was used according to manufacturer in-
structions to measure cell viability. The relative cell viabilities 
were calculated for each drug or drug combination compared 
with vehicle treated control cells. Drug synergy was calculated 
using CompuSyn software by ComboSyn, Inc. (Chou, 2006).
Primary human AML
De-identified viably frozen purified mononuclear cells from pe-
ripheral blood and bone marrow of AML patients were obtained 
from patients at CCH MC. Informed consent was obtained before 
sample banking. Institutional Review Board (IRB) approval for this 
study was obtained at CCH MC. This study was performed in accor-
dance with the Declaration of Helsinki. Six different AML patient 
samples were used with MLL-rearrangements (see Table S3 for 
complete genetic information). 50,000 cells were plated in dupli-
cate in a 96-well plate in IMDM containing 20% heat-inactivated 
FBS plus 10 ng/ml of each SCF, IL3, IL6, TPO, and FLT3. 22d was 
added at the indicated concentrations and cells were incubated 
with drug for 3 d, at which point cell viability was measured by 
MTS assay (Promega) according to manufacturer’s instructions.
Statistical analyses
Except where described for Microarray, RNA-Seq, and RNAi 
screening, all statistical analyses were performed using Prism 6 
(GraphPad Software). For RT-qPCR differences in gene expres-
sion or pulldown, enrichments were evaluated by ratio paired 
parametric t test assuming Gaussian distribution. For ESC core 
gene expression RT-qPCR, differences were evaluated by two-
way ANO VA Holm-Sidak multiple comparisons test. For flow 
cytometric analyses differences in populations were compared 
by two-way ANO VA Bonferroni’s multiple comparisons test. Dif-
ferences in average colony numbers (CFU assays) were evaluated 
statistically using two-way ANO VA Bonferroni’s multiple com-
parisons test or one-way ANO VA Holm-Sidak multiple compar-
isons test as indicated. Differences in target site dual luciferase 
reporter assay repressions were evaluated by two-way ANO VA 
Sidak’s multiple comparisons test. Differences in Skp2 inhibitor 
SLZ P1-41 dosage response were evaluated by multiple unpaired 
t tests with Holm-Sidak multiple testing correction.
Data availability
Microarray and RNA-seq data can be accessed in the Gene Ex-
pression Omnibus accession no. GSE75843.
Online supplemental material
Supplementary information includes five figures and three tables. 
Fig. S1 shows the optimization, characterization, and validation of 
biotinylated miR-196b mimic target pulldowns. Derepression of 
miR-196b pulldown targets in miR196 knockout mice is shown. Fig. 
S2 shows enrichment and depletion scores of shRNA performance 
in the in vivo shRNA screen and examples of shRNA-mediated 
knockdown of miR-196b pulldown target RNA levels in MLL-AF9 
AML. Fig. S3 shows heat map of Phc2 knockdown MLL-AF9 gene 
expression and Cdkn1b knockdown effects on MLL-AF9 tran-
scriptional programming and immunophenotype. Fig. S4 shows 
p27Kip1 induces cyclin/cdk-dependent cell cycle arrest in MLL-r 
AML. Fig. S5 shows p27Kip1 levels in human AML treated with 
SCFSkp2 inhibitors. Table S1 contains 10 tabs of biotinylated miR 
mimic pulldown microarray enrichment results, accession nos. of 
AGO-CLIP data, miR-196 target predictions, details of each hairpin 
in the shRNA screen, average enrichment and depletion scores 
for shRNA screen hairpins, shRNA screen gene ontologies, and 
RNA-seq on E9.5 embryos with limiting miR-196 alleles. Table S2 
contains seven tabs of RNA-seq and GSEA results from Cdkn1b and 
Phc2 knockdown MLL-AF9 AML. Table S3 contains drug synergy 
data, genomic alterations of primary human AML patient sam-
ples, and SNP validation of human AML cell lines.
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